PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 1AN INTERVENTIONAL EF FICACY AND SAFETY, P HASE 2/3, DOUBLE -BLIND, 
2-ARM STUDY TO INVES TIGATE ORALLY ADMINI STERED 
PF-07321332/RITONAVI R COMPARED WITH PLACEBO IN NONHOSPI[INVESTIGATOR_295327] D-19 WHO ARE AT 
INCREASED RISK OF PR OGRESSING TO SEVERE ILLNESS
Study Intervention Number: PF-07321332
Study Intervention Name: N/A
US IND Number: [ADDRESS_359948] Number: 2021- 002895- 38
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]
Protocol Number: C4671005
Phase: 2/3
Brief Title: A Phase 2/3 Efficacy and Safety Study of PF -07321332/Ritonavir in 
Nonhospi[INVESTIGATOR_295328] W ith COVID -19
This document and accompanying materials contain confidential inform ation belonging to [COMPANY_007]. Except 
as otherwise agreed to in w riting, by [CONTACT_22788], you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289] ) 
or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.

PF-[ADDRESS_359949] of country  health authorities and IRBs/ECs and any  protocol administrative 
clarification letter.
Protocol Amendment Summary of Changes Table
Amendment 4 ( 20November 2021 )
Overall Rationale for the Amendment: To remove the second interim anal ysis (70% 
interim analy sis that was added under Amendment 3) from the protocol because the objective 
of the pl anned 45% interim analy sis was met.
Section # and Nam e Description of Change Brief Rationale
Section 1.1
SynopsisSecond interim analysis at 70% 
has been removed, and sample 
size updated to low er it from 
3100 to approximately 3000 
participants due to removal of 
second interim analysis .
Study enrollment will be 
stopped after approximately 
1717 participants are available 
for the primary analysis.The 70% interim analysis has been 
removed because the planned int erim 
analysis objective was achieved.
Section 2 .3.3 
Overall Benefit/Risk 
ConclusionText updated to clarify that the 
E-DMC will be responsible for 
monitoring the safety of 
participants at regularly scheduled 
intervals throughout the duration of 
the study and for assessing efficacy
and futility atthe time of the 
interim analysis.To be consistent with the rest of the 
document.
Section 4.1
Overall DesignSample size updated to low er it 
from 3100 to approximately 
3000 participants due to To provide a more comprehensive 
description of the overall study design
and specifically to reduce the sample size 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 3Section # and Nam e Description of Change Brief Rationale
removal of second interim 
analysis.
Removed second interim 
analysis. in response to the interim analysis 
outcome.
Section 9 
Statistical Considerations9.3.2 Primary 
Endpoint(s)/Estimand(s) 
Analysis: updated to rem ove 
primary analysis being
conducted for 2 planned 
interim analyses .
9.4. Interim Analyses: Second 
interim analysis removed. The 
45% interim analysis
boundary was updated as a 
result, and a sentence added 
regarding boundaries at end of 
trial.
9.5 Sample Size 
Determination: text updated
due to removal of second 
interim analysis: Study
enrollment will be stopped 
after approximately 1717 
partici pants are available for 
the primary analysis.
Total sample size changed 
from [ADDRESS_359950] OF TABLES ................................ ................................ ................................ ..................... 9
1.PROTOCOL  SUMMARY ...................................................................................................10
1.1. Sy nopsis ..................................................................................................................10
1.2. Schema ....................................................................................................................14
1.3. Schedule of Activities .............................................................................................15
2. INTRODUCTION ...............................................................................................................22
2.1. Study  Rationa le.......................................................................................................22
2.2. Background .............................................................................................................22
2.2.1. Nonclinical Studies of PF
-07321332..........................................................23
2.2.2. Clinical Overview .......................................................................................24
2.3. Benefit/Risk Assessment
.........................................................................................24
2.3.1. Risk Assessment .........................................................................................25
2.3.2. Benefit Assessment .....................................................................................27
2.3.3. Overall Benefit/Risk Conclusion ................................................................27
3. OBJECTI VES, ENDPO INTS, AND ESTIMANDS ...........................................................27
4. STUDY DESIGN .................................................................................................................29
4.1. Overall Design .........................................................................................................29
4.2. Scientific Rationale for Study  Design .....................................................................30
4.2.1. Diversity  of Study  Population ....................................................................31
4.2.2. Choice of Contraception/Barrier Requirements .........................................31
4.2.3. Collection of Retained Research Samples ..................................................31
4.3. Justification for Dose ..............................................................................................31
4.4. End of Study  Definition ..........................................................................................32
5. STUDY POPUL ATION
................................ ................................ ................................ ......32
5.1. I nclusion Criteria .....................................................................................................32
5.2. Exclusion Criteria ....................................................................................................34
5.3. L ifesty le Considerations ..........................................................................................36
5.3.1. Contraception ..............................................................................................36
5.4. Screen Failures ........................................................................................................37
5.5. Criteria for Temporarily  Delay ing 
Enrollment/Randomization/Administration of Study  Intervention ...........................37

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 56. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY .................................37
6.1. Study  Intervention(s) Administered ........................................................................37
6.1.1. Administration ............................................................................................38
6.2. Preparation, Handling, Storage, and Accountability ...............................................39
6.2.1. Preparation and Dispensing ........................................................................41
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................41
6.3.1. Allocation to Study Intervention ................................................................41
6.3.2. Blinding of the Sponsor
..............................................................................41
6.3.3. Breaking the Blind ......................................................................................42
6.4. Study  Intervention Compliance ...............................................................................42
6.5. Dose Modification ...................................................................................................43
6.6. Continued Access to Study  Intervention Afte r the End of the Study ......................43
6.7. Treatment of Overdose
............................................................................................43
6.8. Concomitant Therapy ..............................................................................................43
6.8.1. R escue Medicine .........................................................................................44
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................45
7.1. Discontinuation of Study  Intervention ....................................................................45
7.1.1. Potential Cases of Decreased eGFR ...........................................................45
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_359951] to Follow Up
...................................................................................................47
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................47
8.1. Efficacy  Assessments ..............................................................................................48
8.1.1. Participant Diary .........................................................................................48
8.1.2. COVID -
19-Related Medical Visit Details ..................................................48
8.1.3. Daily  Signs and S ymptoms of COVI D
-19 .................................................49
8.1.4. Oxygen Support Details ..............................................................................49
8.1.5. PRO Assessments .......................................................................................49
[IP_ADDRESS]. Global I mpression Questions ....................................................49
[IP_ADDRESS]. WPAI .........................................................................................49
[IP_ADDRESS]. EQ -
5D-5L Scale ........................................................................50

PF-07321332
Protocol C4671005Final Protocol Amendment 4, 20 November 2021
PFIZER CONFIDENTIAL
Page 68.2. Safety Assessments .................................................................................................50
8.2.1. Medical History ..........................................................................................508.2.2. Height and Weight......................................................................................508.2.3. Targeted Physical Examinations.................................................................518.2.4. Vital Signs ..................................................................................................518.2.5. Electrocardiograms.....................................................................................518.2.6. Clinical Safety La boratory Asse ssments ....................................................52
8.2.7. Pregnancy Testing ......................................................................................52
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................53
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......53
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................54
8.3.2. Method of Detecting AEs and SAEs ..........................................................548.3.3. Follow Up of AEs and SAEs......................................................................548.3.4. Regulatory Reporting Requirements for SAEs...........................................558.3.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................55
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................58
8.3.6. Cardiovascular and Death Events...............................................................588.3.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................[ADDRESS_359952].............................................................58
[IP_ADDRESS]. Lack of Efficacy........................................................................58
8.3.9. Medical Device Deficiencies......................................................................588.3.10. Medication Errors .....................................................................................58
8.4. Pharmacokinetics ....................................................................................................598.5. Genetics................................................................................................................... 60
8.5.1. Specified Genetics ......................................................................................60
8.6. Biomarkers ..............................................................................................................61
8.6.1. Specified Gene Expression (RNA) Research .............................................61
CCI
PF-07321332
Protocol C4671005Final Protocol Amendment 4, 20 November 2021
PFIZER CONFIDENTIAL
Page 78.6.3. Specified Metabolomic Research ...............................................................61
8.6.4. Viral Load Assessments .............................................................................61
8.7. Immunogenicity Assessments .................................................................................62
8.8. Health Economics ...................................................................................................62
9. STATISTICAL C ONSIDERATIONS ................................................................................62
9.1. Statistical Hypotheses .............................................................................................63
9.1.1. Estimands....................................................................................................63
[IP_ADDRESS]. Primary Estimand/Co-Primary Estimands ................................[IP_ADDRESS]. Secondary Estimands ................................................................63
9.2. Analysis Sets ...........................................................................................................649.3. Statistical Analyses .................................................................................................65
9.3.1. General Considerations...............................................................................659.3.2. Primary Endpoint(s)/Estimand(s) Analysis ................................................669.3.3. Key Secondary Efficacy Endpoint(s)/Estimand(s) Analysis......................679.3.4. Secondary Endpoint(s)/Estimand(s) Analyses ...........................................68
9.3.6. Other Safety Analyses ................................................................................69
[IP_ADDRESS]. Laboratory .................................................................................[IP_ADDRESS]. Physical Examination and Vital Signs ......................................69
9.4. Interim Analyses .....................................................................................................70
9.5. Sample Size Determination.....................................................................................70
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................72
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............72
10.1.1. Regulatory and Ethical Considerations ....................................................72
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................72
10.1.2. Financial Disclosure .................................................................................73
10.1.3. Informed Consent Process ........................................................................73CCI
CCI
CCI
CCI
PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 810.1.4. Data Protection .........................................................................................74
10.1.5. Committees Structure ...............................................................................74
[IP_ADDRESS]. Data Monitoring Committee ...................................................74
10.1.6. Dissemination of Clinical Study  Data ......................................................75
10.1.7. Data Qualit y Assurance ............................................................................76
10.1.8. Source Documents ....................................................................................78
10.1.9. Study  and Site Start and Closure ..............................................................78
10.1.10. Publication Policy ...................................................................................79
10.1.11. Sponsor’s Qualified Medical Personnel .................................................80
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................81
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recordi ng, 
Evaluating, Follow -Up, and Reporting .....................................................................82
10.3.1. Definition of AE .......................................................................................82
10.3.2. Definition of an SAE ................................................................................83
10.3.3. Recording/Reporting and Follow- Up of AEs and/or SAEs During 
the Active Collection Period ............................................................................85
10.3.4. Reporting of SAEs
....................................................................................88
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................90
10.4.1. Male Participant Reproductive Inclusion Criteria
....................................90
10.4.2. Female Participant Reproductive Inclusion Criteria .................................90
10.4.3. Woman of Childbearing Potential ............................................................91
10.4.4. Contraception Methods .............................................................................92
10.5. Appendix 5: Genetics
............................................................................................94
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -Up Assessments 
and Study  Intervention Rechallenge Guidelines
.......................................................95
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................97
10.8. Appendix 8: 
Prohibited Concomitant Medications That May Result in DDI .......99
10.9. Appendix 9: Signs and Sy mptoms Attributable to COVID -19...........................109
10.10. Appendix 10: Country -Specific Requirements .................................................110
10.10.1. [LOCATION_009] ...................................................................................................110
10.10.2. Japan .....................................................................................................110
10.11. Appendix 11: Protocol Amendment History .....................................................112
10.12. Appendix 12: Abbreviations .............................................................................[ADDRESS_359953] OF TABLES
Table 1. Protocol -Required Safet y Laboratory  Assessments .................................81
Table 2. Signs and Sy mptoms Attributable to COVID -
19 ...................................109

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 101.PROTOCOL SUMMARY 
1.1.Synopsis 
An Interventional Efficacy  And Safet y, Phase 2/3, Double -Blind, 2- Arm Study  To 
Investigate Orally  Administered PF -07321332/Ritonavir Compared With Placebo In 
Nonhospi[INVESTIGATOR_295329] -19 Who Are A t Increased Risk 
Of Progressing To Severe I llness.
Brief Title: A Phase 2/3 Efficacy  and Safet y Study of PF -07321332/Ritonavir in 
Nonhospi[INVESTIGATOR_295330]-19
Rationale
The purpose of this stud y is to evaluate the efficacy and safet y of PF -07321332/ritonavir for 
the treatment of nonhospi[INVESTIGATOR_057], sy mptomatic adult participants with COVID -19 who are at 
increased risk of progressing to severe illness.
Objectives, Endpoints, and Estimands
Objectives Endpoints Estimands
Primary: Primary: Primary: 
To compare the efficacy of 
PF-07321332 /ritonavir toplacebo 
for the treatment of COVID-19 in 
nonhospi[INVESTIGATOR_295331] -19 
who are at increased risk of 
progression to severe disease .Proportion of participants with 
COVID -19 related hospi[INVESTIGATOR_295332] 
28. The difference in proportions of
patients experiencing
COVID -19-related hospi[INVESTIGATOR_295333] 28
innonhospi[INVESTIGATOR_295334] -19who are at 
increased risk of progression to severe 
disease, who did not receive 
COVID -19 therapeutic mAb 
treatment andwere treated ≤3days 
after COVID -[ADDRESS_359954] to
adherenc etorandomized treatment.
Secondary: Secondary: Secondary: 
To describe the safety and 
tolerability of 
PF-07321332 /ritonavir relative to 
placebo in the treatment of 
nonhospi[INVESTIGATOR_295331] -19 
who are at increased risk of 
progression to severe disease .Incidence of TEAEs.
Incidence of SAEs and AEs leading 
to discontinuations.Not applicable. 
To compare the efficacy of 
PF-07321332 /ritonavir toplacebo 
for the treatment of COVID-19 in 
nonhospi[INVESTIGATOR_295331] -19 
who are at increased risk of 
progression to severe disease .Proportion of participants with 
COVID -19-related hospi[INVESTIGATOR_295332] 
28The difference in proportions of 
patients experiencing 
COVID -19-related hospi[INVESTIGATOR_295332] [ADDRESS_359955] to adherence to 
randomized treatment.
To compare 
PF-07321332 /ritonavir to placebo 
for the duration and severity of 
signs and symptoms in 
nonhospi[INVESTIGATOR_295331] -19 
who are at increased risk of 
progression to severe disease .Time (days) to sustained alleviation 
of all targeted signs/symptoms 
through Day 28.
Proportion of participants with 
severe signs/symptoms attributed to 
COVID -19 through Day 28.
Time (days) to sustained resolution 
of all targeted signs/symptoms 
through Day 28.
Duration of each targeted 
COVID -19 sign/symptom.
Progression to a worsening status in 
1 or more self -reported 
COVID -19-associated symptoms 
through Day 28.
Proportion of participants with a 
resting p eripheral oxygen saturation 
≥95% at Days 1 and 5.The absolute difference in median 
time to sustained alleviation or 
resolution of symptoms for all 
nonhospi[INVESTIGATOR_295335] -19 who are at increased risk 
of progression to severe disease. This 
will be estimated irrespective of 
adherence to randomized treatment.
To compare 
PF-07321332 /ritonavir to placebo 
for all -cause mortality in 
nonhospi[INVESTIGATOR_295331] -19 
who are at increased risk of 
progression to severe disease .Proportion of participants with death 
(all cause) through Week 24.Notapplicable .
To determine the PK of 
PF-07321332 in nonhospi[INVESTIGATOR_295336] -19 who are at 
increased risk of progression to 
severe disease .PF-0 7321332 PK in plasma and 
whole blood (if feasible).Not applicable
To describe the viral load in nasal 
samples over time in 
nonhospi[INVESTIGATOR_295331] -19 
who are at increased risk of 
progression to severe disease .Viral titers measured via RT -PCR in 
nasal swabs over time.Not applicable.
To compare 
PF-07321332 /ritonavir to placebo 
for COVID -19-related medical 
visits in nonhospi[INVESTIGATOR_295336] -19 who are at 
increased risk of progression t o 
severe disease .Number of COVID-19 related 
medical visits through Day 28.Not applicable
To compare 
PF-07321332 /ritonavir to placebo 
for COVID -19-related 
hospi[INVESTIGATOR_54992] Number of days in hospi[INVESTIGATOR_295337] -19 
related hospi[INVESTIGATOR_059].Not applicable.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 12Objectives Endpoints Estimands
nonhospi[INVESTIGATOR_295331] -19 
who are at increased risk of 
progression to severe disease .
Overall Design
Brief Summary
This Phase 2/3, randomized, double -blind, placebo -controlled study  in nonhospi[INVESTIGATOR_057], 
symptomatic adult participants with COVID -19 who are at increased risk of progressing to 
severe illness will determine the efficacy , safet y, and tolerability of PF -[ZIP_CODE] 332/ritonavir 
compared with placebo. Eligible participants with a confirmed diagnosis of SARS -CoV -2 
infection will be randomized (1:1) to receive PF-07321332/ritonavir or placebo orall y q12h 
for 5 day s (10 doses total). Randomization will be stratified by  [CONTACT_295403]/are expected to receive COVID -19 therapeutic mAb 
treatment (y es/no) based on the site investigator’s assessment at the time of randomization.
Enrollment of participants who have received/are expected to receive COVID -19 therapeutic 
mAb treatment is expected to be approximately  20% and will be limited to approximately  
25% of participants. Enrollment of participants that had COVID -19 sy mptom onset >3 day s 
prior to randomization is expected to be approxi mately  25% and will be limited to a total of 
approximately  1000 participants.
Number of Participants
Approximately  3000 participants will be randomly assigned to study  intervention.
Note: "Enrolled" means a participant's, or his or her legally  authorized r epresentative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process and screening. A participant will be considered enrolled if the informed consent is 
not withdrawn prior to participating in an y stud y activit y after screening. Potential 
participants who are screened for the purpose of determining eligibility  for the study , but do 
not participate in the study, are not considered enrolled, unless otherwise specified b y the 
protocol. 
Intervention Groups and Duration
Participants will be screened within 48 hours of randomization. Eligible participants will 
receive PF -07321332 plus ritonavir or placebo orally  q12h for 5 day s. The total study  
duration is up to 24 weeks, study  intervention through Day  5 or Day  6, eff icacy  assessments 
through Day  28, a safet y follow -up period through Day  34, and long -term follow -up at 
Weeks 12 and 24.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 13Data Monitoring Committee or Other Independent Oversight Committee: Yes
An independent, E -DMC will review unblinded data to ensure the safet y of participants on an 
ongoing basis throughout the duration of the stud y, as specified in the E -DMC Charter. In 
addition to up to weekly  reviews of safet y, the E -DMC will review the following:
Sentinel cohort safet y review: The E -DMC will review unblinded safet y data after 
approximately  the first [ADDRESS_359956] completed Day  10 of the stud y, at which 
point enrollment will be paused pending E -DMC review of the safety data. After 
review of the sentinel cohort, the frequency  of safety  reviews may  be reduced 
subsequently  based on E -DMC recommendations.
Proof -
of-concept assessment: The E-DMC will review viral load data when 
approximately  200 participants in the primary  analy sis set with evaluable data 
complete the Day  5 assessments. Enrollment will not be paused during review of 
these data but may  be paused or stopped following E -DMC review.
Interim anal ysis: A planned interim anal ysis for efficacy  and futility  will be done 
after approximately  45% of participants in the mITT anal ysis set complete the Day 28 
assessments (ie, 28 day s after randomization). 
Statistical Methods
The cumulative proportion of participants hospi[INVESTIGATOR_295338] -[ADDRESS_359957] 28 day s of the study  will be estimated for each treatment group using 
the Kaplan- Meier method to take account of losses to follow -up and summarized graphically  
for each treatment group. The estimand is then the difference of the proportions in the 2 
groups and its 95% CI  will be presented as well as the associated Wald test. For the 95% CI, 
the corresponding estimate of the standard error is computed using Greenwood’s formula.1
The Greenwood’s formula to estimate the variance of the difference of proportions at Day  28 
is [Var(S PF(28)) + Var(S Placebo (28))]. Instead of dealing with S(t i) the log -log approach to CI 
will be used. The 95% CI will be computed for the estimate of L(t)= log( -log(S(t))), the log
hazard function. 
The above primary  analysis will also be conducted for the planned interim analysis. 
Two-sided 95% CI (adjus ted for the planned interim analysis) and associated p- value for the 
null hy pothesis of no difference between treatment groups will be presented. Significance 
level will be determined using the O’Brien -Fleming approach at the interim analy sis and the 
final analysis. The overall significance level is set at 5% (2 sided).
The estimate of required sample size is based on data from the BLAZE -1 Phase 2/3 trial 
among participants with mild to moderate COVID -19 who were at high risk for progressing 
to severe COVID -19 and/or hospi[INVESTIGATOR_295339].2During the 29- day period 
following enrollment, the proportion of placebo -treated participants with a 
COVID -19-related hospi[INVESTIGATOR_059]/emergency  department visit was 7% in the Phase [ADDRESS_359958] 90% statistical power to show a difference of 3.5% in the 
proportion of participants hospi[INVESTIGATOR_057]/dy ing that did not receive COVID -19 therapeutic mAb 
between the treatment arms (PF -07321332/ritonavir versus placebo), using a 2- sided Ty pe I 
error rate of 5%. Based on the above stud y2, the proportion of hospi[INVESTIGATOR_059]/dea th in the 
placebo arm is assumed to be 7%.
For a [ADDRESS_359959] this difference with 90% 
power at a 2 -sided significance level of 5% was determined to be [ADDRESS_359960] received/are expected to received COVID -19 therapeutic 
mAb treatment is expected to be approximately  20% of participants and will be limited to 
approximately  25% of participants. Enrollment of participants that had COVID-19 s ymptom 
onset >3 day s prior to randomization is expected to be approximately  25%, and will be 
limited to a total of approximately  1000 participants. Assuming a 5% dropout rate, the total 
sample size for this study will be approximately  3000 participants.
Study  enrollment will be stopped after approximately  1717 participants are available for the 
primary  anal ysis.
The primary  estimand is the difference in proportions of patients experiencing COVID -19 
related hospi[INVESTIGATOR_295340] y cause through Day  28 in nonhospi[INVESTIGATOR_295341] -19 who are at increased risk of progression to severe disease, who 
did not receive COVID -19 therapeutic mAb treatment and were treated ≤[ADDRESS_359961] to adherence t o 
randomized treatment. 
1.2.Schema

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 151.3.Schedule of Activities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct eva luations or 
assessments required to protect the well -being of the participant. 
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 12.Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 
21Day 
34LT F/U ET 
(prior 
to Day 
34) Notes
Week 
12Week 
24
Visit Window Day -1 to 
Day 10 days ±1 day ±1 day ±1 day ±2 
days±2 
days±3 
days±7 
days±7 
days±5 days
ELIGIBILITY
Informed consent X See Section 10.1.3 .
Verify inclusion/exclusion 
criteriaX See Section 5.1and Section 5.2.
Demographics and medical 
historyX See Section 8.2.1 .
COVID -19 risk factor 
assessmentX See Appendix 9.
PHYSICAL EXAMINATION & VITAL SIGNS
Targeted physical 
examinationX X X [X] [X] [X] Targeted physical examinations will be completed 
at all in -person visits and on Days 14 and 34 and 
ET (prior to Day 34) if conducted in person. In the 
event that an in -person visit is not feasible at the 
investigational s ite, targeted physical examinations 
may be performed by a licensed HCP at an 
alternate site approved by [CONTACT_093] (eg, the 
participant's home) when feasible.
AEs should be assessed by [CONTACT_3553] a 
telemedicine visit if not feasible via an in -person 
visit.
Previously identified AEs (either by [CONTACT_30230], 
physical exam, or other assessment) should be 
monitored to the extent possible if telemedicine is 
used. 
See Section 8.2.3 andSection 8.2.4 .Vital signs X X [X] X [X] [X] [X]

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 16Visit Identifier
Abbreviations used in this table 
may be found in Appendix 12.Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 
21Day 
34LT F/U ET 
(prior 
to Day 
34) Notes
Week 
12Week 
24
Visit Window Day -1 to 
Day 10 days ±1 day ±1 day ±1 day ±2 
days±2 
days±3 
days±7 
days±7 
days±5 days
Weight, height X Height may be self reported.
See Section 8.2.2 .
ECG X X X X Will be assessed for the first 60 participants 
(sentinel cohort). Further ECG monitoring may 
occur pursuant to E -DMC or FDA 
recommendation after the sentinel cohort safety 
review ( Section [IP_ADDRESS] ).
SeeSection 8.2.5 .
LABORATORY
Hematology X X [X] [X] [X] Screening visit: Laboratory assessments are not 
required at screening unless deemed necessary by 
[CONTACT_295404]. If deemed 
necessary, laboratory assessments at screening will 
be performed at the local laboratory. The medical 
labora tory test abnormalities within [ADDRESS_359962] be closely assessed. If 
abnormalities cannot be verified, consider 
conducting local laboratory testing at screening to 
confirm eligibility for the study.
Baseline laboratory assessments shoul d be 
collected prior to first dose of study intervention. 
If post -screening eGFR is <45 mL/min/1.73m2, the 
participant will be instructed to discontinue any 
remaining study intervention doses as soon as 
study staff become aware of the eGFR results. If 
another baseline laboratory result meets protocol 
Section 5.2exclusionary values and the participant 
is still receiving study treatment, contact [CONTACT_5134].  
Laboratory tests at Days 14 and 34 are required 
only if clinically relevant abnormal laboratory 
values were present from a sample drawn at the 
previous study visit when laboratory assessments 
were performed. Blood chemistry X X [X] [X] [X]
Other laboratory 
assessmentsX X [X] [X] [X]

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 17Visit Identifier
Abbreviations used in this table 
may be found in Appendix 12.Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 
21Day 
34LT F/U ET 
(prior 
to Day 
34) Notes
Week 
12Week 
24
Visit Window Day -1 to 
Day 10 days ±1 day ±1 day ±1 day ±2 
days±2 
days±3 
days±7 
days±7 
days±5 days
Abnormal laboratory values related to AEs should 
be followed until resolution. See Section 8.2.[ADDRESS_359963] X X X A negative urine or serum (β-hCG ) pregnancy test 
must be confirmed at screening for WOCBP only. 
Pregnancy tests will also be done whenever 1 
menstrual cycle is missed during the active 
treatment period (or when potential pregnancy is 
otherwise suspected) and at Day 34 or ET visit.
See Section 8.2.7 .
FSH X FSH is to be performed in female participants <60 
years of age at screening who are not using 
hormonal contraception or hormonal replacement 
therapy, to confirm postmenopausal status. Female 
participants age 50 to 60 years with no menses for 
12 months do n ot need FSH testing to be 
performed to confirm postmenopausal status. 
When FSH testing is required to confirm 
postmenopausal status, a participant may be 
enrolled in the study prior to the test result being 
available as long as the FSH test result confirm s 
postmenopausal status prior to dosing.
See Section 10.4.3 and Appendix 2 .
Rapid antigen testing X Only required if a participant does not have results 
of a positive SARS -CoV -[ADDRESS_359964] that was obtained 
within 5 days prior to randomization.
Refer to Section 5.1.
Viral load assessment X X X X X At baseline, an NP swab will be collected by [CONTACT_295405] -CoV -[ADDRESS_359965] will not be used to 
determine study eligibility. Subsequent NP or 
nasal swabs will be collected on Days 1, 3, 5, 10, 
and 14.
o NP swabs will be collected by [CONTACT_295406] -person visit. Otherwise, a nasal 

PF-07321332
Protocol C4671005Final Protocol Amendment 4, 20 November 2021
PFIZER CONFIDENTIAL
Page 18Visit Identifier
Abbreviations used in this table 
may be found in Appendix 12 .Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 
21Day 
34LT F/U ET 
(prior 
to Day 
34) Notes
Week 
12Week 
24
Visit Window Day -1 to 
Day 10 days ±1 day ±1 day ±1 day ±2 
days±2 
days±3 
days±7 
days±7 
days±5 days
swab will be self collected by [CONTACT_2416].
•See Section 8.6.4 .
 
  
 
 
 
 
PK
PK sample (PF-07321332) X X •On Day 1, one blood sample for PK will be 
collected 30 to 90 minutes postdose if feasible for the participant to remain at the site.
•On Day 5, one blood sample for PK will be 
collected. The preferred time of sample collection is predose up to 2 hours before study intervention administration; if a predose sample collection is not possible, collect this sample at anytime during 
the visit, even after study intervention has been 
administered.
•Refer to Section 8.4 .
Optional PK sampling 
([PF-07321332] collected 
via home health, site visit, 
or self collected using Tasso; in a subset of participants, if feasible)X •PK sample(s) will be collected either during in-
person visit (a single blood sample collected at any 
time on either Days 2, 3, or 4) or self-collected by [CONTACT_295407] (selected sites) at the following timepoints:
o Day 2 before the evening dose, 
o Day 3 after the morning dose at the 
following times: 1 sample between 30 to 90 minutes, 1 sample between 2 to 6 hours, 
and 1 sample 8 to 12 hours after the dose CCI
CCI
CCI
PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 19Visit Identifier
Abbreviations used in this table 
may be found in Appendix 12.Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 
21Day 
34LT F/U ET 
(prior 
to Day 
34) Notes
Week 
12Week 
24
Visit Window Day -1 to 
Day 10 days ±1 day ±1 day ±1 day ±2 
days±2 
days±3 
days±7 
days±7 
days±5 days
(the last sample should be collected before 
the evening dose).
Refer to Section 8.4
RANDOMIZATION X
STUDY INTERVENTION
Study intervention 
administrationDay 1 through Day 5 (10 
doses total)If 1 dose was administered on Day 1, study 
intervention administration should end on Day 6.
See Section 6.1.
STUDY PROCEDURES & ASSESSMENTS
Collect/update secondary 
contact[CONTACT_295408] X X X X X X The investigator will capture contact [CONTACT_295409] [ADDRESS_359966] if 
the participant is unable to be reached after 
multiple attempts.
At baseline, the investigator will also request 
contact [CONTACT_295410] 
C4671006 as applicable.
Record supplemental oxygen 
requirementsX X X X X X X X See Section 8.1.4 .
Study kit dispensed and 
participant instructed on its 
useX
Participant-completed study 
diary (COVID -19 signs and 
symptoms and global 
impression questions )Every day from Day 1 through Day 28 See Section 8.1.1 and Section [IP_ADDRESS] .
Global impression questions will be answered 
every day from Day 1 through Day 28 after 
COVID -19 signs and symptom diary is completed.  
These additional questions will only be assessed in 
participants who enroll after the sentinel cohort 
(ie, the first 60 participants) as available.
WPAI X X X X Will only be assessed in participants who enroll 
after the sentinel cohort (ie, the first 60 
participants) as available.
See Section [IP_ADDRESS] .

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 20Visit Identifier
Abbreviations used in this table 
may be found in Appendix 12.Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 
21Day 
34LT F/U ET 
(prior 
to Day 
34) Notes
Week 
12Week 
24
Visit Window Day -1 to 
Day 10 days ±1 day ±1 day ±1 day ±2 
days±2 
days±3 
days±7 
days±7 
days±5 days
EQ-5D-5L X X X X X X Will only be assessed in participants who enroll 
after the sentinel cohort (ie, the first 60 
participants) as available.
See Section [IP_ADDRESS] . 
Staff review of study diary X X X X X X X X SeeSection 8.1.1 .
Participant-completed study 
intervention logDay 1 through Day 5/6 Study intervention log should be completed daily 
on Days 1 through Day 6 if only 1 dose was 
administered on Day 1. 
See Section 6.4.
Record COVID -19-related 
medical visitsX X X X X COVID -19-related medical visits a participant has 
attended since the last assessment will be 
collected.
See Section 8.1.2.
Retrieval of u nused study 
intervention and empty 
study intervention containers X [X] [X] X If the Day [ADDRESS_359967] dose of 
study intervention, the s tudy intervention log, 
emptystudy intervention containers, and unused 
study interv ention should be returned at the next 
in-person visit.
See Section 6.4.
Study intervention 
accountabilityX [X] X X 
[if 
needed]Study intervention accountability is only 
performed at the Day 14 visit if the participant 
administered treatment after the Day 5 visit was 
conducted. If the Day 14 visit is not an in -person 
visit, study intervention accountability will then be 
performed during the Day 34 visit.
SeeSection 6.4.
Contraception check X X X X X X X SeeSection 5.3.1 .
Vital status check X X X
Long -term follow -up 
telemedicine interviewX X Staff will ask participants if they are experiencing 
COVID -[ADDRESS_359968] a 
vital status check.
CONCOMITANT TREATMENT(S)
Prior/concomitant 
medicationsX X X X X X X X All prescription and over-the -counter medications 
including vaccines taken by [CONTACT_295411]-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 21Visit Identifier
Abbreviations used in this table 
may be found in Appendix 12.Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 
21Day 
34LT F/U ET 
(prior 
to Day 
34) Notes
Week 
12Week 
24
Visit Window Day -1 to 
Day 10 days ±1 day ±1 day ±1 day ±2 
days±2 
days±3 
days±7 
days±7 
days±5 days
30days before study entry (considered prior 
treatment) will be recorded. 
Concomitant therapi[INVESTIGATOR_295342] 34 visit.
Refer to Section 6.8.
Adjunctive therapeutic 
procedures X X X X X X X X Will be collected through the Day 34 visit .
Serious and nonserious ae 
monitoringX X [X] X X X X X X AEs should be assessed by [CONTACT_3553] a 
telemedicine visit if not feasible via an in -person 
visit 
Refer to Section 8.3.
Site staff should, in discussion with participants, determine the most appropriate location to conduct study visits, whether in-person or remotely by [CONTACT_144891]. In -person 
visits should take place at the investigational site. If investigational site in -person visit is not feasible, then alternate venues may include the participant's home or an alternate, 
noninvestigational site location approved by [CONTACT_093]. If an in -person visit is held at a location other than the investigational site, in certai n situations the assigned HCP 
performing the visit may be unable to complete all assessments. In these cases, a telemedicine visit should also occur to per form the remaining assessments. Remote visits can 
be conducted using a telemedicine system approved f or use at the site.  
Assessments indicated in brackets [X] will be performed only for in -person visits.
Screening procedures may be done from Day -1 to Day 1. In many cases, all screening procedures can be completed in <24 hours. For these participants, s creening procedures 
may be completed on the same calendar day as randomization and Baseline/Day [ADDRESS_359969] dose of study inter vention.
Baseline assessments should be performed before the administration of the first study intervention.
Day 1is the start of dosing.
For Study Intervention Administration : Participants will receive study intervention for 5 days (10 doses total). The first dose will be administered at the Baseli ne/Day 1 visit 
during the in -person visit, if possible. All subseq uent doses (ie, 9) will be self -administered outside the study clinic (eg, at home). 
Screening , Baseline , and Day 5 visits will be conducted in -person (at the investigational site approved by [CONTACT_1720] a remote location, including a participant’ s home).
Day [ADDRESS_359970] 60 participants (sentinel cohort) and thereafter only if a PK sample (not using Tasso) is collected by a n HCP or if ECG is 
required.
Day 3 and Day 5 visits should be conducted on separate calendar da ys.
Day 10, Day 21, Week 12 and Week 24 visits will be conducted by [CONTACT_295412]. Telemedicine visits may be converted to an in -person visit at the discretion of the 
investigator.
Day [ADDRESS_359971] 60 participants (sentinel cohort). Thereafter the visit may be conducted in -person or by [CONTACT_144891]. After the sentinel 
cohort the visit must be conducted in person only if ECG is required.
Day 34 visit will be conducted in -person or by [CONTACT_295412].
Early Term ination prior to Day 34 visit will be conducted in -person or by [CONTACT_295412].

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 222.INTRODUCTION
PF-07321332, a potent and selective SARS- CoV -2 3CL  protease inhibitor, is being 
investigated as an oral antiviral treatment of COVID-19.
2.1.Study Rationale 
The purpose of this stud y is to evaluate the efficacy and safet y of PF -07321332/ritonavir for 
the treatment of nonhospi[INVESTIGATOR_057], sy mptomatic adult participants with COVID -[ADDRESS_359972] (approximately  80%) cases are as ymptomatic 
or mild,7patients who are hospi[INVESTIGATOR_21391] -[ADDRESS_359973] significant morbidity  and 
mortality ,8,9and are at increased risk of developi[INVESTIGATOR_295343], ARDS, acute cardiac 
injury , thromboembolic events, hy percoagulab ility, and/or kidney  injury .10-13Moreover, 
other comorbidities, such as hy pertension, obesit y, and diabetes, as well as older age and 
male sex increase the risk for worse outcomes.14
Although there are s ymptomatic and/or supportive t reatments for COVID -19, few antiviral 
drugs are available or in late-stage development to help treat COVID- 19 in patients with mild 
to moderate COVID -19. Existing compounds, such as hy droxy chloroquine and 
lopi[INVESTIGATOR_054]/ritonavir, have been evaluated as potenti al treatment options for COVID -19, but 
have not demonstrated benefit or efficacy  beyond the SOC.15-17The FDA has approved IV 
remdesivir,18an antiviral drug with activity  against SARS -CoV -2, for hospi[INVESTIGATOR_295344] D-19. However, remdesivir monotherapy  may  not be sufficient in all subsets of 
patients19across the COVID -[ADDRESS_359974] the efficacy of mAb based regimens.
There is thus a high unmet need for antiviral agents that could be used for the treatment of 
nonhospi[INVESTIGATOR_295345] D-19. Such agents, particularl y those that target highly 
conserved viral targets, don’t require administration in a healthcare setting, and wi th a 
risk/benefit profile supportive of administration to a broad patient population will 
significantl y add to the treatment armamentarium for COVID -19.
The coronavirus 3CL  protease is a virall y encoded enzy me that is critical to the 
SARS -CoV -2 replication cycle, analogous to other obligatory  virally  encoded proteases 
(eg,HIV Protease, HCV Protease).27Mutagenesis experiments with other coronaviruses and 
pi[INVESTIGATOR_295346] -CoV -2 (pi[INVESTIGATOR_295347] -like supercluster) have 
demonstrated that the activity  of the 3CL protease (or the corresponding pi[INVESTIGATOR_295348] 
3Cenzyme) is essential for viral replication. No close human analogs of coronavirus 3CL  
enzy mes are known, suggesting that appropriat e 3CL  inhibitors may  function as selective 
inhibitors of SARS -CoV -2 and other coronaviruses as therapeutic agents.
PF-07321332, a potent and selective inhibitor of the SARS- CoV -2 3CL  protease, is being 
developed as an oral treatment in patients with COVID-19.
In this stud y, PF -07321332 will be coadministered with ritonavir. Ritonavir is a strong 
CYP3A4 inhibitor, and is being coadministered with PF-07321332 to achieve exposures 
sufficient to suppress viral replication through the entire dosing interval (ie, Ctrough>EC 90). 
Ritonavir is not expected to have an y antiviral activity  against the SARS- CoV -2 virus.
2.2.1. Nonclinical Studies of PF-07321332
Data from nonclinical studies support the planned clinical trials with PF -07321332; these 
studies are described in the IB.[ADDRESS_359975] article -related findings identified in the safet y pharmacology studies included changes in 
locomotor acti vity and transient higher respi[INVESTIGATOR_295349]-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 24dose, as well as minor and transient hemod ynamic changes (increased blood pressure and 
decreased heart rate) at the high dose in cy nomolgus monkey s. The potential effects on s afety 
pharmacology  parameters are monitorable in the clinic, and no correlated clinical signs or 
histopathological findings in the relevant organs were observed in the [ADDRESS_359976] article -related changes in ECG parameters 
(HR, RR -, PR-, QRS -, QT- , QTc -intervals) or ECG morphology  in that study .
2.2.2. Clinical Overview
C4671001 ([STUDY_ID_REMOVED]) is an ongoing FIH single and multi ple dose escalation study  to 
evaluate the safet y, tolerability , and PK of PF -07321332 in healthy  adult participants. 
Preliminary  data from this study  collected as of 07 April 2021 (SAD) and 
14April 2021(MAD) in a total of 31 participants who were randomized and treated with 
PF-
07321332 or placebo indicate that the clinical safet y profile of PF -07321332 appears to 
be acceptable at single doses up to 1500 mg alone and up to 750 mg administered with 
ritonavir (100 mg at -12h, 0h, 12h), and at repeated daily  doses administered orally  for 10 
days of up to 500 mg PF -07321332 BID with 100 mg ritonavir BID.
Preliminary  PK data on Day  1, Day  5 and Day  10 following multiple oral administration of 
PF-07321332/ritonavir 75/100 mg, 250/100 mg, and 500/[ADDRESS_359977] common reported AE, occurring in 4 participants across treatment 
groups. A total of 5 treatment related TEAEs were observed in Part -2:MAD.
Across treatment groups, blood TSH increased in 3 participants, and 2 participants reported 
dysgeusia. The 3 participants with elevated TSH results did not experience related clinical 
symptoms and the free T4 results remained within reference range. No SAEs or deaths were 
reported based on these preliminary  safety  data as of 07 April 2021 and 14 April 2021.
Current evidence indicates that the clinical safet y profile of PF -07321332 is acceptable at 
single doses up to 1500 mg alone and up to 750 mg administered with ritonavir (100 mg 
at -12h, 0h, 12h), and at repeated daily  doses administered orall y for 10 days of up to 500 mg 
PF-07321332 BID with 100 mg ritonavir BID.
2.3.Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of PF -07321332 may be found in the investigator’s brochure, which is the 
SRSD for this study . The SRSD for ritonavir is the USPI  [INVESTIGATOR_295350].

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 252.3.1. Risk Assessment
Potential Risk of Clinical SignificanceSummary of Data/Rationale for RiskMitigation Strategy
Study Intervention(s) PF-07321332
Emesis Sporadic emesis was observed at ≥100 mg/kg/day of 
PF-07321332 in the 15 -day NHP toxicology study.AEs will be monitored and participants may 
receive antiemetics.
Hem odynamic and inflammatory effects Low level inflammation (increase in fibrinogen) in 
15-day NHP toxicology study and changes in 
platelets, globulin and albumin/globulin ratio and 
coagulation system (increase in PT and aPTT) in 
14-day rat toxicology study.In addition to vital signs and clo se observation for 
AEs, fibrinogen, platelets, D -dimer, PT and aPTT, 
albumin, and total protein will also be monitored.
Refer to Section 8.3.8.
TSH elevationsTSH changes observed with the administration of 
PF-07321332 during study C4671001TSH and T4 (free) w ill be monitored.
Refer to Section 8.3.8 .
Study Intervention(s): Ritonavir
Gastrointestinal disturbances (including 
diarrhea, nausea, vomiting and abdominal pain)Frequently reported adverse reaction in HIV -positive 
patients who are HIV -positive at 600 mg BID.Lower dose of 100 mg twice daily is used in this 
study. There will be close observation of AEs. In 
addition to ongoing review of AEs by [CONTACT_456], 
an E-DMC will review safety data as described in 
Section [IP_ADDRESS] .
Taking study intervention with food may improve 
tolerability.
Neurological disturbances (eg, paresthesia, 
including oral paresthesia, dysgeusia and 
dizziness)Frequently reported adverse reaction in patients who 
are HIV -positive at 600 mg BID.Lower dose used in this study. There w ill be close 
observation of AEs.  
In addition to ongoing revie w of AEs by [CONTACT_103], an E -DMC will review safety data as 
described in Section [IP_ADDRESS] .
Rash (most commonly reported as erythematous 
and maculopapular, followed by [CONTACT_108135])Frequently reported adverse reaction in patients who 
are HIV -positive at 600 mg BID.Lower dose used in this study. There w ill be close 
observation of AEs and monitoring through 
targeted physical exams. If needed therapeutic 
interventions per SoC may be p rovided.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 26Potential Risk of Clinical SignificanceSummary of Data/Rationale for RiskMitigation Strategy
Fatigue/Asthenia Frequently reported adverse reaction in patients who 
are HIV -positive at 600 mg BID.Lower dose used in this study. There w ill be close 
observation of AEs. Fatigue (low  energy or 
tiredness) will be assessed through collection of 
daily signs and symptoms and w ill also be 
assessed through targeted physical examinations 
when performed during the study visits.

PF-[ADDRESS_359978] SARS -CoV -2 antiviral activity  in vitro and is intended 
to reduce virus titers, thereb y reducing the duration and severit y of s ymptoms and the risk of 
mortality  in SARS -CoV -2 infected patients. On this basis, the potential benefit to individual 
study  participants who receive the stud y intervention may include a shorter time to clinical 
recovery , prevention of hospi[INVESTIGATOR_059], and a lower probability  of progressing to more severe 
illness or death. The potential benefit of th e stud y is that it may  provide a new treatment 
option for nonhospi[INVESTIGATOR_41374] -19 who are at increased risk for progression 
to severe disease and hospi[INVESTIGATOR_059]. In the context of the global pandemic public health 
emergency , this treatment could play  an important role in alleviating current pressures on 
health care s ystems globally .  
2.3.3. Overall Benefit/Risk Conclusion
Taking into account the current COVID -19 global pandemic and the high burden of both 
mortality  and morbidity  and the potential for future epi[INVESTIGATOR_295351], the lack of readil y 
available outpatient treatment options, and the measures taken to minimize risk to 
participants in this study , the potential risks identified in association with PF -07321332 are 
justified by  [CONTACT_295413] d benefits that may  be afforded to participants with COVID -19. An 
independent E -DMC will be responsible for monitoring the safet y of participants at regularl y 
scheduled intervals throughout the duration of the study  and for assessing efficacy  and 
futility  at the time of the planned interim anal ysis according to the E- DMC C harter.
3.OBJECTIVES, ENDPOINTS, AND ESTIMANDS
Objectives Endpoints Estimands
Primary: Primary: Primary: 
To compare the efficacy of 
PF-07321332 /ritonavir to
placebo for the treatment of 
COVID -19in nonhospi[INVESTIGATOR_295336] -19 who are at 
increased risk of progression to 
severe disease .Proportion of participants with 
COVID -19 related hospi[INVESTIGATOR_295352] 28. The difference in proportions of
patients experiencing
COVID -19-related hospi[INVESTIGATOR_295333] 28
innonhospi[INVESTIGATOR_295353] -19who are at 
increased risk of progression to 
severe disease ,who did not receive 
COVID -19 therapeutic mAb 
treatment and were treated ≤3days 
after COVID -[ADDRESS_359979] to
adherence torandomized treatment.
Secondary: Secondary: Secondary: 
To describe the safety and 
tolerability of 
PF-07321332 /ritonavir relative to 
placebo in the treatment of 
nonhospi[INVESTIGATOR_295354] -19 who are at increased Incidence of TEAEs.
Incidence of SAEs and AEs leading 
to discontinuations.Not applicable. 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 28Objectives Endpoints Estimands
risk of progression to severe 
disease .
To compare the efficacy of 
PF-07321332 /ritonavir to
placebo for the treatment of 
COVID -19in nonhospi[INVESTIGATOR_295355] -19 who are at 
increased risk of progression to 
severe disease .Proportion of participants with 
COVID -19-related hospi[INVESTIGATOR_295356] 28The difference in proportions of 
patients expe riencing 
COVID -19-related hospi[INVESTIGATOR_295332] [ADDRESS_359980] to adherence to 
randomized treatment.
To compare 
PF-07321332 /ritonavir to 
placebo for the duration and 
severity of signs and symptoms 
in nonhospi[INVESTIGATOR_295354] -19 who are at increased 
risk of progression to severe 
disease .Time (days) to sustained alleviation 
of all targeted signs/symptoms 
through Day 28.
Proportion of participants with 
severe signs/symptoms attributed to 
COVID -19 through Day 28.
Time (days) to sustained resolution 
of all targeted signs/symptoms 
through Day 28.
Duration of each targeted 
COVID -19 sign/symptom.
Progression to a worsening status in 
1 or more self -reported 
COVID -19-associated symptoms 
through Day 28.
Proportion of participants with a 
resting p eripheral oxygen saturation 
≥95% at Days 1 and 5.The absolute difference in median 
time to sustained alleviation or 
resolution of symptoms for all non-
hospi[INVESTIGATOR_295335] -19 who are at increased risk 
of progression to severe disease. This 
will be estimated irrespective of 
adherence to randomized treatment.
To compare 
PF-07321332 /ritonavir to 
placebo for all -cause mortality in 
nonhospi[INVESTIGATOR_295354] -19 who are at increased 
risk of progression to severe 
disease .Proportion of participants with 
death (all cause) through Week 24.Notapplicable .
To determine the PK of 
PF-07321332 in nonhospi[INVESTIGATOR_295336] -19 who are at 
increased risk of progression to 
severe diseas e.PF-07321332 PK in plasma and 
whole blood (if feasible).Not applicable.
To describe the viral load in 
nasal samples over time in 
nonhospi[INVESTIGATOR_295354] -19 who are at increased 
risk of progression to severe 
disease .Viral titers measured via RT- PCR in 
nasal swabs over time.Not applicable.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 29Objectives Endpoints Estimands
To compare 
PF-07321332 /ritonavir to 
placebo for COVID -19-related 
medical visits in nonhospi[INVESTIGATOR_295336] -19 who are at 
increased risk of progres sion to 
severe disease .Number of COVID-19 related 
medical visits through Day 28.Not applicable.
To compare 
PF-07321332 /ritonavir to 
placebo for COVID -19-related 
hospi[INVESTIGATOR_295357] -19 who are at increased 
risk of progression to severe 
disease .Number of days in hospi[INVESTIGATOR_295337] -19 
related hospi[INVESTIGATOR_059].Not applicable.
4.STUDY DESIGN
4.1.Overall Design
This Phase 2/3, randomized, double -blind, placebo -controlled study  in approximately  
3000 symptomatic participants with COVID -19 who are nonhospi[INVESTIGATOR_295358] , safet y, and tolerability of PF -07321332/ritonavir compared with placebo. El igible 
participants with a confirmed diagnosis of SARS- CoV - 2 infection will be randomized (1:1) 
to receive PF- 07321332 and ritonavir or placebo orally  q12h for 5 day s (10 doses total). 
Randomization will be stratified b y geographic region and b y whether pa rticipants have 
received/are expected to receive treatment with COVID-19 therapeutic mAbs based on the 
site investigator’s assessment at time of randomization. Throughout the study  period, 
provision will be made to allow study  visits to be conducted at a p articipant’s home or at 
another nonclinic location approved by [CONTACT_295414] a clinic visit.  
Enrollment of participants who have received/are expected to receive COVID -19 therapeutic 
mAb treatment is expected to be approximately  20% and will be limited to approximately  
25% of participants. Enrollment of participants that had COVID -19 sy mptom onset >3 day s 
prior to randomization is expected to be approximately  25% and will be limited to a total of 
approximately  1000 participants.
The total study  duration is up to 24 weeks and includes a screening period of no more than 
48hours, study  intervention through Day  5 or Day 6, efficacy  assessments through Day  28, a 
safet y follow- up period thro ugh Day  34, and long -term follow up at Weeks 12 and 24. 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 30An independent E -DMC will review unblinded data to ensure the safet y of participants on an 
ongoing basis throughout the duration of the stud y, as specified in the E -DMC Charter. In 
addition to up to weekly  reviews of safet y, the E -DMC will review the following:
Sentinel cohort safet y review : The E -DMC will review unblinded safet y data after 
approximately  the first [ADDRESS_359981] completed Day  10 of the stud y, at which 
point enrollment will be pa used pending E -DMC review of the safety data. After 
review of the sentinel cohort, the frequency  of safety  reviews may  be reduced 
subsequently  based on E -DMC recommendations.
Proof -of-concept assessment : The E -DMC will review viral load data when 
approxima tely 200 participants in the primary  analy sis set with evaluable data 
complete the Day 5assessments. Enrollment will not be paused during review of 
these data but may  be paused or stopped following E -DMC review.
Interim anal ysis: A planned interim anal ysis for efficacy  and futility  with a sample 
size re -estimation will be done after approximately  45% of participants in the mITT 
analysis set complete the Day  28 assessments (ie, 28 day s after randomization). 
Subsequent to the planned interim analy sis, there will be [ADDRESS_359982] of an investigational agent on reducing 
COVID -19 related hospi[INVESTIGATOR_165348] (all cause), and, as a secondary  endpoint, the 
duration and severity  of COVID -19-a ssociated s ymptoms because participants are 
symptomatic upon entry  to this study . Previous studies with mAbs directed against the 
SARS -CoV -2 spi[INVESTIGATOR_2531] (S) protein that have received an EUA from the US FDA showed 
efficacy  in reducing hospi[INVESTIGATOR_4355]/or dea th in high -risk participants, as well as 
reducing SARS CoV -2 shedding on NP swabs and time to sy mptom resolution.3,25,26Efficacy 
assessments (including par ticipant reported COVID -19 sy mptoms and severity , 
COVID -
19-related medical visits, and vital status) will be collected through Day  28. The 
symptom endpoint includes those recommended by  [CONTACT_295415]-19, and which are expected to be d ynamic and 
improve with effective anti
-SARS -CoV -2 therapy. NP/nasal swabs will be collected at 
specified timepoints to assess viral load over time.
This study  uses a randomized, double -blind, placebo -controlled design, which is a well -
accepted approach for evaluating efficacy  in a clinical research setting. Placebo was selected 
as the comparator because there is no -globall y approved SoC treatment for this patient 
population as of June 2021. Participants in either treatm ent group may receive SoC therapy  
so long as it is not prohibited under Section 5.1 or Appendix 8 .Beca use the NIH COVID -19 
Treatment Guidelines panel29recom mends use of the available EUA mAb therapi[INVESTIGATOR_295359]- 19 who are high risk of clinical 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 31progression, participants enrolled in the US (and other countries, depending on availability ), 
may receive COVID-[ADDRESS_359983] received/are expected 
to receive a COVID -19 therapeutic mAb treatment (y es/no).
Because of limited in -human dosing before this Phase 2/3 study , an early  safet y analysis 
(with enrollment pause) will be conducted b y the E- DMC following enrollment of a sentinel 
cohort of 60 participants. Thereafter, if no clinically  significant safet y signals are identified, 
enrollment will resume with the E -DMC conducting frequent safet y reviews as outlined in 
the E -DMC Charter. 
4.2.1. Diversity of Study Population
Reasonable attempts will be made to enroll participants to ensure the stud y population is 
representative of the patient population that w ill be treated with PF -07321332/ritonavir in 
clinical practice.
4.2.2. Choice of Contraception/Barrier Requirements 
Studies to evaluate the developmental toxicity  of PF -[ADDRESS_359984] not been conducted. 
Therefore, the use of a highl y effective method of contrace ption is required (see Appendix 4 ).
4.2.3. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for further anal yses which may , for 
example, provide greater understanding of t he study  intervention.
4.3.Justification for Dose
A dosing regimen of 300 mg PF -07321332 coadministered with 100 mg ritonavir q12h 
administered orall y for 5 days will be evaluated in this study . Dose selection for this study  
included consideration of all relev ant available preclinical and clinical data, including 
repeat -dose toxicology  studies, clinical safet y, and PK data from the Phase 1 study  
(C4671001), and in vitro pharmacology  studies with PF -07321332.
A preliminary  population PK model was developed from the Phase 1 (C4671001) PK data. 
Following the first dose of 300 mg of PF-07321332 coadministered with 100 mg ritonavir 
q12h, median C trough of unbound (free) PF -07321332 are predicted to be approximately  
289ng/mL (equivalent to 933 ng/mL total), ie, appro ximately  3-fold higher than the in vitro 
EC 90of 90.4 ng/mL  determined in dNHBE cells (equivalent to 181 nM, f u, human=0.310). At 
this dose, for a h ypothetical intersubject variability of 60%, more than 95% of the 
participants are predicted to maintain free PF- 07321332 concentrations above the in vitro 
EC 90over the 12- hour dosing interval.
The selected duration is based on the effectiveness demonstrated following 5 -day 
administration of other antiviral agents used in the treatment of acute respi[INVESTIGATOR_121875], 
such as remdesivir for SARS -CoV -2 and oseltamivir for influenza.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 32Preliminary  safet y data from study  C4671001, collected up to 07 April 2021 and 
14April 2021, showed an acceptable safet y profile for single doses of PF -07321332 ranging 
from 150 mg t o 1500 mg dosed alone and of 250 mg and 750 mg dosed with ritonavir 
(100 mg administered at -12h, 0h, 12h) and for [ADDRESS_359985] completed the study  if he/she has completed all periods of 
the study , including the last visit as shown in the SoA .
5.STUDY PO PULATION
This study  can fulfill its objectives only  if appropriate participants are enrolled, including 
participants across diverse and representative racial and ethnic backgrounds. Use of a 
prescreener for stud y recruitment purposes will include collectio n of information, that 
reflects the enrol lment of a diverse participant population including, where permitted under 
local regulations, age, sex, and race, and ethnicity. The following eligibility criteria are 
designed to select participants for whom partic ipation in the study  is considered appropriate. 
All relevant medical and nonmedical conditions should be taken into consideration when 
deciding whether a particular participant is suitable for this protocol. 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1.
Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex:
1.Participants ≥18 y ears of age (or the minimum country -specific age of consent if >18) 
at the time of the Screening Visit.
WOCBP may  be enrolled.
All fertile participants must agree to use a highl y effective method of 
contraception. Refer to Appendix 4 for reproductive criteria for male 
(Section
10.4.1) and female ( Section 10.4.2) participants.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 33Type of Participant and Disease Characteristics:
2.Confirmed SARS -CoV -2 infection as determined by  [CONTACT_937]-PCR in any  specimen 
collected within 5 day s prior to randomization.
Note: RT -PCR is the preferred method; however, with evolving approaches to 
confirmation of SARS -CoV -[ADDRESS_359986] performed at screening.
3.Initial onset of signs/s ymptoms attributable to COVID- [ADDRESS_359987] 1 of the specif ied signs/sy mptoms attributable to 
COVID -19 present on the day  of randomization (see Appendix 9 for criteria).
4.Has at least 1 characteristic or underl ying medical condition associated with an 
increased risk of develop
ing severe illness from COVID -19 including:
≥60 y ears of age;
BMI >25;
Current smoker (cigarette smoking within the past 30 day s) and history  of at 
least 100 lifetime cigarettes;
Immunosuppressive disease (eg, bone marrow or organ transplantation or 
primar y immune deficiencies) OR prolonged use of immune -weakening 
medications:
oHas received corticosteroids equivalent to prednisone ≥[ADDRESS_359988] 14 consecutive day s within 30 day s prior to study  entry .
oHas received treatment with biologics (eg, infliximab, ustekinumab), 
immunomodulators (eg, methotrexate, 6MP, azathioprine) or cancer 
chemotherap y within 90 day s prior to study  entry .
oHIV infection with CD4 cell count <200 mm3 and a viral load less than 
400 copi[INVESTIGATOR_014]/mL
Chronic lung disease (if asth ma, requires daily  prescribed therapy );
Known diagnosis of h ypertension;
CVD, defined as history  of any  of the following: my ocardial infarction, 
stroke, TIA, HF, angina with prescribed nitrogl ycerin, CABG, PCI, carotid 
endarterectom y, and aortic by[CONTACT_6476];
Type 1 or Ty pe 2 diabetes mellitus;
CKD provided the participant does not meet Exclusion Criterion 5;
Sickle cell disease;

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 34Neurodevelopmental disorders (eg, cerebral pals y, Down’s s yndrome) or other 
conditions that confer medical complexity  (eg, genetic or m etabolic 
syndromes and severe congenital anomalies);
Active cancer, other than localized skin cancer, including those requiring 
treatment as long as the treatment is not among the prohibited medications 
that must be administered/continued during the trial period;
Medical -related technological dependence (eg, CPAP [not related to 
COVID -19]).
5.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
Inform ed Consent:
6.Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions listed in the I CD and in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.History  of hospi[INVESTIGATOR_295360]-19.
2. Current need for hospi[INVESTIGATOR_295361] 48 
hours after randomization in the clinical opi[INVESTIGATOR_91382] (see 
Section 8.1.2.)
3.Prior to current disease epi[INVESTIGATOR_1865], an y confirmed SARS -CoV -[ADDRESS_359989] (antigen or nucleic acid) from an y specimen 
collection.
4.Known medical history  of active liv er disease (other than nonalcoholic hepatic 
steatosis), including chronic or active hepatitis B or C infection, primary  biliary  
cirrhosis, Child
-Pugh Class B or C, or acute liver failure.
5.Receiving dialy sis or have known moderate to severe renal impairment
[ie,eGFR <45mL/min/1.73 m2within 6 months of the screening visit, using the 
serum creatinine -based CKD -EPI [INVESTIGATOR_14420]].30
6.Known HIV infection with a viral load greater than 400 copi[INVESTIGATOR_014]/mL  or taking 
prohibited medications for HIV treatment (from known medical history  within past 
6months of the scre ening visit) ( Appendix 8 ).

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 357.Suspected or confirmed concurrent active s ystemic infection other than COVID -19 
that may  interfere with the evaluation of response to the study  intervention.
8.Any comorbidity  requiring hospi[INVESTIGATOR_5478]/or surgery  within 7 day s prior to study  
entry , or that is considered life threatening within 30 day s prior to study  entry , as 
determined b y the investigator.
9.History  of hypersensitivity  or other contraindication to any  of the components of the 
study  intervention, as determined b y the investigator.
10.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory  abnormality  that may  increase the risk 
of study  participation or, in the investigator’s judgment, make the participant 
inappropriate for the study .
Prior/Concomitant Therapy:
11.Current or expected use of an y medications or substances that are highly dependent 
on CYP3A4 for clearance and for which elevated plasma concentrations may be 
associated with serious and/or life -threatening events during treatment and for [ADDRESS_359990] dose of PF -07321332/ritonavir (See Appendix 8).
12.Concomitant use of an y medications or substances that are strong inducers of 
CYP3A4 are prohibited within [ADDRESS_359991] dose of PF -07321332/ritonavir 
and during study  treatment (see Appendix 8 ).
13.Has received or is expected to receive convalescent COVI D
-19 plasma.
14.Has received or is expected to receive an y dose of a SARS -CoV -2 vaccine before the 
Day 34 visit.
15. Is unwilling to abstain from participating in another interventional clinical study  with 
an investigational compound or device, including those for COVID -19 therapeutics, 
through the long- term follow -up visit.
Prior/Concurrent Clinical Study Experience:
16.Previous administration with any investigational drug or vaccine within 30 days (or as 
determine d by [CONTACT_19970]) or [ADDRESS_359992] dose of study  
intervention used in this study  (whichever is longer). 
17.Known prior participation in this trial or other trial involving PF- 07321332.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 36Diagnostic Assessments:
18.Known history  of any of the following abnormalities in clinical laboratory  tests 
(within past 6 months of the screening visit): 
AST or ALT level ≥2.[ADDRESS_359993];
Total bilirubin ≥[ADDRESS_359994] (≥[ADDRESS_359995] for Gilbert’s sy ndrome);
Absolute neutrophil count <1000/mm3.
GFR <45 mL/min/1.73 m 2 within 6 months of the screening visit, using the serum 
creatinine -based CKD -EPI [INVESTIGATOR_14420]30
Note: If the investigator suspects the participant may  have any  of the above 
laboratory  values, confirmatory  tests should be performed at screening to confirm 
eligibility  before the first dose of study  intervention. See Appendix 2 for more details.
19.Oxygen saturation of <92% on room air obtained at rest within 24 hours prior to 
randomization.
Note: for a potential participant who regularl y receives chronic supplementary 
oxygen for an underl ying lung condition, oxy gen saturation should be measured while 
on their standard home ox ygen supplementation.
Other Exclusions:
20.Females who are pregnant or breastfeeding.
21.Investigator site staff or [COMPANY_007] employ ees directl y involved in the conduct of the 
study , site staff otherwise supervised b y the investigator, and their respective family 
members. 
5.3.Lifestyle Considerations
5.3.1. Contraception
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 ,Section 10.4.4 ) and will confirm that the participant has been instructed in its 
consistent and correct use. At time points indicated in the SoA, the investigator or designee 
will inform the participant of the need to use highly  effective contraception consistently  and 
correctly  and document the conversati on and the participant’s affirmation in the participant’s 
chart (participants need to affirm their consistent and correct use of at least 1 of the selected 
methods of contraception) considering that their risk for pregnancy  may  have changed since 
the last visit. I n addition, the investigator or designee will instruct the participant to call 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 37immediately  if the selected contraception method is discontinued or if pregnancy  is known or 
suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to study  intervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participan ts to meet 
the CONSORT publishing requirements and to respond to queries from regulatory  
authorities. Minimal information includes demography , screen failure details, eligibility  
criteria, and an y SAE.
Individuals who do not meet the criteria for participa tion in this study  (screen failure) may  
not be rescreened.  
5.5.Criteria for Temporarily Delaying Enrollment/Randomization/Administration of 
Study Intervention 
Not applicable.
6.STUDY INTERVENTION(S) AND CONCOMITANT THERAPY
Study  intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, medical device(s), or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to PF-07321332 150 mg tablets 
(or PF -07321332 100 mg tablets) and matching placebo and ritonavir 100 mg capsules and 
matching placebo
6.1.Study Intervention(s) Administered
Study Interventions(s)
Intervention Name [INVESTIGATOR_16335]-07321332 Placebo for 
PF-07321332Ritonavir Placebo for 
Ritonavir
ARM Nam e
(group of patients 
receiving a specific 
treatm ent (or no 
treatm ent)PF-07321332/ritonavir Placebo PF-
07321332/ritonavirPlacebo
Type drug placebo drug placebo
Dose Form ulation tablet tablet capsule capsule
Unit Dose Strength(s) 150 mg, 100 mg 0 mg 100 mg 0 mg

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 38Study Interventions(s)
Dosage Level(s) 300 mg q12h for 5 
days0 mg q12h for 
5 days100 mg q12h for 5 
days0 mg q12h for 
5 days
Route of 
Administrationoral oral oral oral
Use experimental placebo experimental placebo
IMP or NIMP IMP IMP IMP IMP
Sourcing Provided centrally by 
[CONTACT_295416] m anual.Provided 
centrally by 
[CONTACT_295417].Provided centrally by 
[CONTACT_295417].Provided 
centrally by 
[CONTACT_295417].
Packaging and 
LabelingStudy intervention will 
be provided in blister 
wallets. Each wallet 
will be labeled as 
required per country 
requirement. Products 
will be provided w ith 
blinded labels.Study 
intervention 
will be 
provided in 
blister w allets. 
Each wallet 
will be labeled 
as required per 
country 
requirement.Study intervention 
will be provided in 
HDPE bottles. Each 
bottle w ill be labeled 
as required per 
country requirement.Study 
intervention 
will be 
provided in 
HDPE bottles. 
Each bottle 
will be labeled 
as required 
per country 
requirement.
Current/Former 
Nam e(s) or Alias(es)PF-07321332 NA ritonavir NA
Study Arm(s)
Arm  Title PF-07321332/ritonavir Placebo
Arm  Type experimental placebo
Arm  Description Participants will receive 
PF-07321332/ritonavir 300 
mg/100 mg every 12 hours for 
5days.Participants will receive 0 mg every 
12 hours for 5 days
Associated Intervention Labels PF-07321332/ritonavir Placebo
6.1.1. Administration
PF-07321332 150 mg tablets or placebo for PF -07321332, will be administered for 5 day s 
with ritonavir 100 mg or placebo for ritonavir capsules. Participants will be dispensed 
1blister wallet of PF -07321332 150 mg or placebo for PF -07321332 tablets and 1 bottle of 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 39ritonavir or placebo for ritonavir capsules. Participants will be given clear dosing instruction 
to take:
2 tablets of PF- 07321332 150 mg or placebo for PF -07321332 q12h
1 capsule of ritonavir 100 mg or placebo for ritonavir q12h. 
For the sentinel cohort only (Phase 2) : Some partici pants in this sentinel cohort may  
receive PF -07321332 100 mg tablets or placebo for PF -07321332. In this instance, 
PF-07321332 100 mg tablets or placebo for PF -07321332 will be administered for 5 day s 
with ritonavir 100 mg or placebo for ritonavir capsules . Participants will be dispensed 
1blister wallet of PF -07321332 100 mg or placebo for PF -07321332 tablets and 1 bottle of 
ritonavir or placebo for ritonavir capsules. Participants will be given clear dosing instruction 
to take:
3 tablets of PF- 07321332 10 0 mg or placebo for PF -07321332 q12h
[ADDRESS_359996] dose of stud y intervention on Day  1, preferably  during the 
in-person visit; that is, participants should take 2 tablets of PF-07321332 150 mg or placebo 
(or 3 tablets of PF -07321332 100 mg tablets, if sentinel cohort) or placebo and [ADDRESS_359997] dose. The remaining 
doses should be taken every  12 hours (±30 minutes). Participants will swallow the study  
intervention whole a nd will not manipulate or chew the study  intervention prior to 
swallowing. Participants may  take the study  intervention with or without food. Taking study  
intervention with food may  improve tolerability . Refer to the IP Manual for additional dosing 
and adm inistration instructions.
If a dose is delay ed, it should be taken as soon as possible, but no later than 4 hours before 
the next scheduled dose. Participants should not double up the next dose of study  drug in 
order to “make up” what had been missed. Dosi ng should be stopped at the end of the 
treatment period (10 doses total). An y remaining tablets and/or capsules at the end of 5 days 
(or 6 day s if onl y one dose was administered on Day 1) should be returned.
6.2.Preparation, Handling, Storage, and Accountabili ty
1.
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  interventions received and any  
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participant s enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 

PF-[ADDRESS_359998] be kept in the participant’s source 
documents/medical records.  For investigational sites using ground transportation to 
deliver study  intervention to participants, stability data reveal that if the total duration 
of transit is less than [ADDRESS_359999] participants on the proper storage requirements for take -home 
study  intervention.
7.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stu dy intervention accountability , reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records), such as the 
IPAL or sponsor -approved equivalent. All study  interventions will be accounted for 
using a stud y intervention a ccountabilit y form/record. All study  intervention that is 
taken home b y the participant, both used and unused, must be returned to the 
investigator b y the participant. Returned study intervention must not be redispensed 
to the participants.
8.Further guidanc e and information for the final disposition of unused study  
interventions are provided in the I P manual. All destruction must be adequately  
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that t he materials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y [COMPANY_007].

PF-[ADDRESS_360000] in the bottle and blister cards, as appropriate 
provided throughout the course of dosing and return the bottle and blister cards, as 
appropriate to the site at the next study  visit.
Study  intervention and placebo will be dispensed by  [CONTACT_295418]. The study  intervention will be administered in a blinded fashion 
to the part icipants.
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study Intervention
Allocation of participants to treatment groups will proceed through the use of an IRT s ystem 
(IWR). The site personnel (study  coordinator or specified designee ) will be required to enter 
or select information including but not limited to the user’s ID and password, the protocol 
number, and the participant number. The site personnel will then be provided with a 
treatment assignment, randomization number, and DU o r container number when stud y 
intervention is being supplied via the I RT s ystem. The I RT sy stem will provide a 
confirmation report containing the participant number, randomization number, and DU or 
container number assigned. The confirmation report must be stored in the site’s files. 
Study  intervention will be dispensed at the study  visits summarized in the SoA. 
Returned study  intervention must not be redispensed to the study  participants.
The study  specific IRT reference manual and IP manual will provide the contact [CONTACT_19974] s ystem.
6.3.2. Blinding of the Sponsor
The majority of sponsor staff will be blinded to study  intervention allocation. There will be 
an unblinded team s upporting the interactions with, and the anal yses for, the E -DMC while 
the study  is ongoing. The team will consist of at a minimum a clinician, statistician and 
programmer(s) and will be separate from the blinded members of the study team.  
An unblinded submissions team will be responsible for preparing unblinded anal yses 
and documents to support regulatory  activities that may  be required while the study  is 
ongoing. This team will only  be unblinded at the group level and not have access to 
individual parti cipant assignments.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 42Unless efficacy  is demonstrated at an interim analy sis, the study  will be unblinded after all 
participants complete the Day 34 visit (or ET prior to Day  34 visit), and analy ses through 
Day 34, including the primary  efficacy  endpoint ana lyses, will be conducted.  
Details of the unblinded sponsor staff supporting the E -DMC and the timing of unblinding 
will be outlined in the Unblinding Plan.
6.3.3. Breaking the Blind 
The I RT will be programmed with blind breaking instructions. I n case of an eme rgency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’s 
treatment assignment is warranted. Participant safety must alway s be the first consideration 
in making such a determination. If the investigator decides t hat unblinding is warranted, the 
investigator should make every  effort to contact [CONTACT_1152] a 
participant’s treatment assignment unless this could delay  further management of the 
participant. If a participant’s treatment assignment is unblinded, the sponsor must be notified 
within [ADDRESS_360001] information 
and further details on the use of the IRT s ystem.
6.4. Study Intervention Compliance
Participants will be issued an electronic study  intervention diary  (ie, participant -completed 
study  intervention log) and will be educated to record the date and time of their study  
intervention dosing preferably  at the time of first dose.
Compliance with study intervention will be assessed by  [CONTACT_295419], review 
of the electronic study  intervention diary , and discussion with the participant.
Study  intervention administration, including any  deviation(s) from the prescribed dosage 
regimen, should be recorded in the CRF
.
A record of the number of study  intervention tablets/capsules dispensed to and taken by  [CONTACT_19977]. Intervention start and stop dates will also be recorded in the CRF.
The following noncompliance cases will be considered medication errors (See 
Section
8.3.10 ):
Participants interrupting study  intervention for 2 consecutive doses;
Participants taking either PF -07321332/placebo or ritonavir/placebo alone for 2 
consecut ive doses.
Participants who have an overall study  intervention compliance of <80% or >115%. 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 43In addition to the above -listed medication errors, any  deviation from protocol specified 
dosing (eg, missed single dose or partial dose) should be recorded as a pr otocol deviation and 
the investigator or designee is to counsel the participant and ensure steps are taken to 
improve compliance.
6.5.Dose Modification 
Dose modification for PF -07321332/ritonavir is not allowed. 
6.6. Continued Access to Study Intervention After t he End of the Study
No intervention will be provided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of PF -07321332/placebo greater than 900 mg or ritonavir/placebo 
greater than 300 mg within a 24-hour time period will be considered an overdose.
There is no specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_22840] 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of study  intervention 
(whichever is longer).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE.
5.Obtain a blood sample for PK anal ysis within [ADDRESS_360002] dose of 
study  intervention if requested by  [CONTACT_7195] (determined on a case -by-case 
basis).
Decisions regarding dose 
interruptions or modifications will be made by  [CONTACT_78256].   
6.8.Concomitant Therapy
Hormonal contraceptives that meet the requirements of this study  are allowed to be used in 
participants who are WOCBP (see Appendix 4 ).
Permitted During the Study
All participants may  receive SoC therapy  for COVID- 19, in addition to study  intervention, 
unless listed as prohibited medic ation (see Appendix 8 ) or as defined in Section 5.2. SoC 
therap y is defined as an y therap y that is approved and used as indicated b y the local 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 44regulatory  authorities (including approvals for emergency  use, compassionate use, or through 
similar regulatory  guidance), or any  therapy  as recommended by  a relevant national (or a 
reputa ble international) scientific body  (eg, WHO, ECDC, CDC, NI H). Sites should consult 
with the sponsor if a new SoC option becomes available after stud y initiation. I nvestigator 
should ensure that an y recommended SoC therap y is not a strong inducer of CYP3A4 or 
highl y dependent on CYP3A4 for clearance.
In countries in which mAb are authorized or approved and considered the SoC, all 
participants will be referred locall y for treatment with mAb as deemed appropriate b y the 
investigator and local guidelines and this referral should be documented. Notwithstanding, 
this mAb treatment is not mandatory  for participation in this study .
Prohibited During the Study
Participants should not receive convalescent COVID -19 plasma treatment for COVID-19, 
during the stud y period. COVID -19 vaccinations are permitted after the Day  34 visit.
PF-07321332 and ritonavir are both primarily  metabolized by  [CONTACT_9058] P450 (CYP) 3A4. 
Therefore, concomitant use of an y med ications or substances that are strong inducers of 
CYP3A4 are prohibited within 28 day s prior to dosing of study  intervention and during study  
treatment.
Additionally , PF-07321332 and ritonavir are inhibitors of CYP3A4. Therefore, medications 
highl y depend ent on CYP3A4 for clearance and for which elevated plasma concentrations 
may be associated with serious and/or life- threatening events are not permitted during dosing 
of PF -07321332/ritonavir and for [ADDRESS_360003] dose of PF -07321332/ritonavir. 
Because ritonavir [ADDRESS_360004] medical supportive care may  be pro vided to manage AEs. 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 457.DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention. Reasons 
for permanent discontinuation of study  intervention include the following.  
AE of Grade 3 severit y or greater and considered by [CONTACT_295420];
SAE considered b y the investigator to be related to study intervention;
Requirement for prohibited concomitant medication;
Death;
Pregnancy ;
Study  terminated by  [CONTACT_3211];
Withdrawal by  [CONTACT_295421]
Miss more than [ADDRESS_360005] be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures , posttreatment study  follow -up, 
and/or future collection of additional information.
7.1.1. Potential Cases of Decreased eGFR
If postscreening eGFR is <45 mL /min/1.73m2the participant will be instructed to discontinue 
any remaining study  intervention doses as soon as study  staff become aware of the eGFR 
results. 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 467.2.Participant Discontinuation/Withdrawal From the Study 
A participant may  withdraw from the study  at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further stud y procedures;
Lost to follow -up;
Death;
Study  terminated by  [CONTACT_3211].
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early discontinuation visit applies only to participants who are enrolled/randomized and 
then are prematurely  withdrawn from the study . Participants should be questioned regarding 
their reason for withdrawal.  
If a participant withdraws from the study , he/she may  request destruction of any  rema ining 
samples taken and not tested, and the investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participants who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol specified follow up procedures. The onl y 
exceptio n to this is when a participant specificall y withdraws consent for any further contact 
[CONTACT_78258]. Participants should notify  the investigator in writing of the decision t o withdraw 
consent from future follow up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from st udy procedures and/or 
posttreatment study  follow up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital stat us only  as appropriatel y directed in 
accordance with local law.

PF-[ADDRESS_360006] be taken if a participant fails to be available for a required stud y 
visit:
The site must attempt to contact [CONTACT_14315]. Counsel the participant on the importance of maintaining the 
assigned visit schedule, and ascertain whether the participant wishes to and/or should 
continue in the study ;
Before a participant is deemed lost to follow up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y specific procedures.  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure , as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICD may be utilized for screening or baseline 
purposes provided the procedures met the protocol -specified cr iteria and were performed 
within the time frame defined in the SoA.

PF-[ADDRESS_360007] daily  COVID -19 signs and s ymptoms, study  intervention administration, and PRO 
assessments in the study  diary . 
Participants will receive daily  reminders to complete entries on their own as specified in t he 
SoA. The diary  should be completed at approximately  the same time every day . Staff will 
review the participant’s study  diary  online as specified in the SoA .
The diary  allows recording of these assessments on ly within a fixed time window (eg, 24h), 
thus providing an accurate representation of the participant’s experience at that time. The 
participant is able to make revisions to incorrect entries before pressing the save or submit 
button. I n the event that a participant becomes aware of an error in data after the entry  is 
saved, a change to the diary  data may  only be made by  [CONTACT_295422] a data 
clarification form. Data reported in the participant diary  will be transferred electronically  to a 
third-party vendor, where they will be available for review b y investigators and the sponsor 
or delegate at all times via an internet -based portal.
8.1.2. COVID -
19-Related Medical Visit Details
Details of participants’ COVID -
19-related medical visits (ie, hospi[INVESTIGATOR_12191], practitioner’s 
office, home healthcare services, telemedicine, urgent care, emergency  room ≤24h, extended 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 49care facility  stay) will be collected during study  visits, including level of care (ICU status) 
and dates of utilization, including admission an d discharge, as applicable. 
Hospi[INVESTIGATOR_31561] >24 hours of acute care, in a hospi[INVESTIGATOR_295362] , including Emergency  Rooms or temporary  facilities instituted to address medical 
needs of those with severe COVID -19 during the COVID -19 pandemic. This includes 
specialized acute medical care unit within an assisted living facility  or nursing home. This 
does not include hospi[INVESTIGATOR_295363]/or clinical trial 
execution.
8.1.3. Daily Signs and Symptoms of C OVID -19
On Day  1, participants will complete the study  diary  before receiving study intervention. 
Participant assessment of COVID -19-related s ymptoms should be recorded at approximately  
the same time each day  as specified in the SoA and described in Section 8.1.1 .
COVID -
19-related s ymptoms will be evaluated in accordance with FDA guidelines 
(Appendix 10
).31Participants will record a daily  severit y rating of their symptom severity 
over the past 24 hours based on a 4 -point scale in which 0 is reported if no symptoms were 
present; 1 if mild; 2 if moderate; and 3 if severe. 
Vomiting and diarrhea will each be rated on a 4 -point frequency  scale where 0 is reported for 
no occurrence, 1 for 1 to 2 times, 2 for 3 to 4 times, and 3 for 5 or greater. 
Sense of smell and sense of taste will each be rated on a 3- point L ikert scale where 0 is 
reported if the sense of smell/taste was the same as usual, 1 if the sense of smell/taste was 
less than usual, and 2 for no sense of smell/taste. 
Targeted COVID -19-associated s ymptoms are a subset of these s ymptoms ( Appendix 9 ). 
8.1.4. Oxygen Support Details 
Type of oxy gen support (eg, ox ygen supplementation received at home, mechanical 
ventilation received in hospi[INVESTIGATOR_307]) will be collected.
8.1.5. PRO Assessments
[IP_ADDRESS]. Global Impression Questions
Three questions will be included in the ePRO to assess patient-reported global impression 
items: a) return to usual health; b) return to usual activities; and c) overall COVID -19-related 
symptoms.31
[IP_ADDRESS]. WPAI
COVID -19 impacts manual and office -based work, and results in missed work due to illness 
or quarantine and loss in of productivity .32The Work Productivity  and Activity  Impairment 
Questionnaire: General Health (GH) is being implemented for COVID -19 (ie., WPA I
-
COVID -19) in order to evaluate change from baseline in work burdens.  The WPAI -GH has 
demonstrated validity , reliability  and sufficient predictive value to measure the impact of 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 50disease on absenteeism, presenteeism, and overall productivity  in a manner t hat can also be 
monetized.33
The WPAI -COVID -19 consists of 6 questions that refer to the following assessments for 
work productivity : 1 = currentl y emplo yed, 2 = hours missed due to heal th problems, 3 = 
hours missed other reasons, 4 = hours actually  worked, 5 = degree health affected 
productivity  while working (using a 0 to 10 VAS), and 6 = degree health affected 
productivity  in regular unpaid activities. The recall period for questions 2 through 6 is 7 day s. 
Four main outcomes will be generated from the WPAI -COVID -19 and reported as: 1) 
percent work time missed due to COVID -19 for those who are currentl y employ ed, 2) 
percent impairment while working due to COVID -[ADDRESS_360008] 7 days, 3) percent overall work impairment due to COVID -19 
for those who are currently  employ ed, and 4) percent activity  impairment due to COVID -19 
for all respondents.33The WPAI -COVID -19 will be completed during site visits, as specified 
in the SoA .
[IP_ADDRESS]. EQ-
5D-5L Scale
The EQ -5D is a validated, standardized, generic instrument that is a preference -based health 
related qualit y of life questionnaire in cost effectiveness and health technologies assessment 
(HTA).34-36Recently , a version was developed called EQ -5D- 5L with 5 response levels on 
each dimension compared to the 3 response levels in the Euroquol Quality  of L ife 
5-Dimension 3 -Level Scale (EQ -5D-3L).34-40
Measurement properties of the EQ -5D- 5L demonstrated to be a valid version of the 3 level 
questionnaire that improved measurements by  [CONTACT_1583] d iscriminatory  power, reducing the 
ceiling, and establishing convergent and known groups validity .34,36,38,39Both the EuroQol 
EQ-5D- 3L and EQ -5D- 5Lversions are well established instruments used to measure health 
states and utilities in various diseases areas and assess mobility , self care, usual activities, 
pain/discomfort, anxiety /depression and health status using a VAS.37,41The EQ-5D- 5L 
should be com pleted as described in the Schedule of Activities.
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any  
perceived safety  issues.
8.2.1. Medical History
Medical history  in addition to COVI D-19 disease history  and demographics will be collected 
at screening. Smoking status will be collected. Complete medication history of all 
prescription or nonprescript ion drugs (including vaccinations), and dietary  and herbal 
supplements taken within [ADDRESS_360009] dose will be collected.
8.2.2. Height and Weight
Height and weight will also be measured and recorded at screening. Height may  be self 
reported.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 518.2.3. Targeted Physical Examinations
A targeted ph ysical examination will include, at a minimum, cardiopulmonary  assessments. 
Investigators should pay  special attention to any  previously  identified or new AE/targeted 
condition that the participant has experienced.
Physical examination findings collected during the study  will be considered source data and 
will not be required to be reported, unless otherwise noted. An y untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.3.[ADDRESS_360010] 
for the participant in a quiet setting without distractions (eg, television, cell phones).
Vital signs are to be taken before blood collection for laboratory  tests.
Each participant will also be supplied with a pulse oximeter to be used based on the 
instruction and medical judgment of the site investigator.
8.2.5. Electrocardiograms
Standard 12
-lead ECGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex. Alternative lead placement methodology  using torso leads (eg, Mason- Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant 
has rested quietl y for at least 10 minutes in a supi[INVESTIGATOR_2547]. Triplicate 12- lead ECGs 
obtained at a minimum at baseline/Day 1, should be obtained approximately 2 to 4 minutes 
apart.
ECG data may  be submitted to a central laborator y for measurement. The final ECG report 
from the central laboratory should be maintained in the participant’s source documentation 
and be the final interpretation of the ECG recording. An y clinically  significant changes from 
the baseline/Day  1 ECG may  potentiall y be AEs ( Appendix 7 ) and should be evaluated 
further, as clinicall y warranted

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 52If a) a postdose QTcF interval remains ≥60msec from the baseline andis >450 msec; or 
b)an absolute QT value is ≥500 msec for an y schedul ed ECG for greater than 4 hours (or 
sooner, at the discretion of the investigator); or c) QTcF intervals get progressively  longer, 
the participant should undergo continuous ECG monitoring.
In some cases, it may  be appropriate to repeat abnormal ECGs to rul e out improper lead 
placement as contributing to the ECG abnormality. It is important that leads be placed in the 
same positions each time in order to achieve precise ECG recordings. If a machine read QTc 
value is prolonged, as defined above, repeat measur ements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern are listed in Appendix 7.
8.2.6. Clinical Safety Lab oratory Assessments 
See Appendix [ADDRESS_360011] be conducted in accordance with the laboratory  manual and the SoA. 
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y issues.  
Laboratory  safet y parameters will be graded according to the Division of AIDS (DAIDS) 
Table for Grading the Severity  of Adu
lt and Pediatric Adverse Events42, version 2.1. The 
investigator must review the labora tory report, document this review, and record any  
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unles s judged b y the investigator to be more severe than expected for 
the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_360012] dose of study  intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix [ADDRESS_360013] 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA . 
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced. Pregnancy  tests will also be done whenever 1 menstrual cy cle is missed during 
the active treatment period (or when potential pregnancy  is otherwise suspected). Pregnancy  

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 53tests may  also be repeated if requested b y IRBs/ ECs or if required b y local regulations. If a 
urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy  test 
is required. In such cases, the participant must be excluded if the serum pregnancy  result is 
positive.
If a particip ant requiring pregnancy  testing cannot visit a local laboratory , a home urine 
pregnancy  testing kit with a sensitivity  of at least 25 mI U/mL may  be used by  [CONTACT_295423], if compliant with local regulatory  requirements. The pr egnancy  
test outcome should be documented in the participant’s source documents/medical records. If 
the pregnancy  test is positive, the EDP should be reported ( Section [IP_ADDRESS]). Confirm that the 
participant is adhering to the contraception method(s) required in the protocol.
8.3.
Adverse Events, Serious Adverse Events, and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authorized representative), or they  may  arise from clinical findings of the Investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or cau sed the participant to discontinue 
the study  intervention (see Section 7.1). 
During the active collection period as described in Section 8.3.1, each participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow up 
information in an expedited fashion.
8.3.1.
Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins fr om the time the participant provides informed consent, 
which is obtained before the participant’s participation in the study  (ie, before undergoing 
any study  related procedure and/or receiving study  intervention), through and including a 
minimum of [ADDRESS_360014] SAE Report Form.
Investigators are not obligated to activel y seek information on AEs or SAEs after the 
participant has concluded study participation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the stud y, and he/she 
considers the event to be reasonabl y related to the study  intervention, the investigator must 
promptly  report the SAE to [COMPANY_007] using the CT SAE Report Form.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.[ADDRESS_360015] SAE Report Form immediately  upon
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24
hours of it being available.
[IP_ADDRESS]. Recording Nonserio us AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_360016] on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when de tecting AEs and/or SAEs. Open
-ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow up (as defined in Section 7.3).
In general, follow up information will include a description of the event in sufficient detail to 
allow for a complete medica
l assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 

PF-[ADDRESS_360017] the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs , and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]Rs according to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary  or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study  and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Br eastfeeding, and 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact [CONTACT_273478]. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include exposure during pregnancy , exposure during 
breastfeeding, and occupational exposure.
Any such exposure to the study  intervention under study  are reportable to [COMPANY_007] Safet y 
within 24 hours of investigator awareness.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after disco ntinuing 
study  intervention. 
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception.
A female is found to be pregnant while being exposed or having been exposed to 
study intervention due to environmental exposure. Below are examples of 
environmental EDP:  
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_78262].
A male famil y member or h ealthcare provider who has been exposed to the study  
intervention by  [CONTACT_78263].
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, ir respective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the in vestigator must report 
this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until a minimum
of [ADDRESS_360018] administration of study  intervention .
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to t he initial EDP Supplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the s tructural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 57Abnormal pregnancy  outcomes are considered SAEs. If the out come of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion including miscarriage and missed abortion;
Neonatal deaths that occu r within [ADDRESS_360019] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -
up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paterna l exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention.
A female is found to be bre astfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by [CONTACT_78262].  
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study , so the information is not recorded on a 
CRF. How ever, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in a ccord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Occupational Exposure
The investigator must report any  instance of occupational exposure to [COMPANY_007] Safet y within 24 
hours of the investigator’s awareness using the CT SAE Report Form, regardless of whether 
there is an associated SAE. Since the information about the occupational exposure does not 
pertain to a participant enrolled in the study , the information is not recorded on a CRF; 
however, a cop y of the completed CT SAE Report Form must be maintained in the 
investigator site file.
8.3.6.
Cardiovascular and Death Events
Not applicable.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qual ifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
Adverse events of special interest (AESIs) are examined as part of routine safet y data review 
procedures throughout the clinical trial and as part of signal detection processes.
AESI s include hemody namic events, inflammatory  events, and thy roid- related events.
All AESI s must be reported as an AE or SAE following the procedures described in 
Sections 8.3.[ADDRESS_360020] SAE Report Form.
[IP_ADDRESS]. Lack of Efficacy
The investigator must report signs, s ymptoms, and/or clinical sequelae resulting from lack of 
efficacy . Lack of efficacy  or failure of expected pharmacological action is reportable to 
[COMPANY_007] Safety  only if associated with an SAE .  
8.3.9.
Medical Device Deficiencies
Not applicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by  [CONTACT_19995], or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under study  may  occur in clinical trial settings, such as 
medication errors.

PF-[ADDRESS_360021] SAE Report 
Form to [COMPANY_007] Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant expos ure to the study  intervention;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study  participant.
The administration of expi[INVESTIGATOR_214312]
The administration of an incorrect study  interv ention
The administration of an incorrect dosage
The administration of study  intervention that has undergone temperature excursion 
from the specified storage range, unless it is determined by  [CONTACT_214348]
The administration of study  intervention consistent with the medication error 
descriptions in Section 6.4.
Such medication errors occurring to a stud y participant are to be captured on th e medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours.
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on the AE page of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_360022] SAE Report 
Form only when associated with an SAE.
8.4.Pharmacokinetics 
Blood samples of approximately  4mL, to provide a minimum of 1.5 mL  plasma, will be 
collected for measurement of plasma concentrations of PF -
07321332 as specified in the SoA. 
In a subset of participants, additional optional PK samples may  be collected via home health 
visit, in -clinic visits, or self -collected whole blood microsample (Tasso device) to measure 
concentrations of PF- 07321332. I nstructions for the collection and handling of biological 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 60samples will be provided in the laboratory  manual or by  [CONTACT_456]. The actual date and 
time (24- hour clock time) of each sample will be recorded.
The actual times may  change, but the number of samples will rema in the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of 
samples obtained ≤[ADDRESS_360023] time of the collection is noted on the 
source document and the CRF. This protocol deviation does not apply  to samples that are 
specified to be collected “at an y time.”
Samples will be used to evaluate the PK of PF-07321332. Samples collected for an alyses of 
PF-07321332 concentration may  also be used to evaluate safet y or efficacy aspects related to 
concerns arising during or after the study , for metabolite identification and/or evaluation of 
the bioanal ytical method, or for research related to the s tudy intervention(s) and COVID -19. 
Samples may  also be used to evaluate the concentration of ritonavir.
Genetic anal yses will not be performed on these plasma samples unless consent for this was 
included in the informed consent. Participant confidentiality will be maintained.
Samples collected for measurement of plasma concentrations of study  intervention will be 
analyzed using a validated anal ytical method in compliance with applicable SOPs. Potential 
metabolites may  be anal yzed with either validated or ex ploratory  methods.
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity .Any deviations from the PK sample 
handling procedure (eg, sample collection and processing step s, interim storage or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor. 
On a case -by-case basis, the sponsor may  make a determination as to whether sample 
integrit y has been compromised.
Drug concentration i nformation that would unblind the study  will not be reported to 
investigator sites or blinded personnel until the study  has been unblinded.
Any changes in the timing or addition of time points for any  planned stud y assessments must 
be documented and approv ed by  [CONTACT_185618], but will not constitute a protocol amendment. The I RB/EC will 
be informed of an y safety issues that require alteration of the safet y monitoring scheme or 
amendment of the ICD.
8.5.Genetics
8.5.1. Specified Genetics
Genetics (specified anal yses) are not evaluated in this study .

PF-07321332
Protocol C4671005Final Protocol Amendment 4, 20 November 2021
PFIZER CONFIDENTIAL
Page 61 
 
 
 
 
 
8.6. Biomarkers
Collection of samples for biomarker research is also part of this study. 
The following samples for biomarker research are required and will be collected from all 
participants in this study as specified in the SoA:
•NP/nasal swab will be collected to measure SARS CoV-2 viral load by [CONTACT_937]-PCR. 
•Residual NP/nasal viral load samples may be used for SARS CoV-2 viral sequencing.
•Residual NP/nasal viral load samples may be used for SARS CoV-2 infectivity assays 
and phenotypic analyses. 
 
8.6.1. Specified Gene Expression (RNA) Research 
Specified gene expression (RNA) research is not included in this study
 
 
 
 
8.6.3. Specified Metabolomic Research 
Specified metabolomic research is not included in this study.
8.6.4. Viral Load Assessments 
An NP/nasal swab will be collected per the SoA, and may be analyzed to measure SARS-
CoV-2 RNA by [CONTACT_937]-PCR. Residual viral load samples may be utilized for viral sequencing to assess for signs of viral evolution and evaluation of potential genetic viral variants CCI
CCIC
CI
PF-07321332
Protocol C4671005Final Protocol Amendment 4, 20 November 2021
PFIZER CONFIDENTIAL
Page 62(eg, 3CL gene) or immune responses, SARS CoV-2 infectivity assays, and additional 
molecular analysis.
Residuals of all samples may be banked for future research. Storage and shippi[INVESTIGATOR_295364].
 
  
 
 
 
 
8.7. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.8. Health Economics
Health economics/medical resource utilization and health economics parameters will be 
evaluated in this study ( Section 8.1.2 . and Section 8.1.3 ).
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a SAP, which will be maintained by [CONTACT_456]. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.CCI
PF-07321332
Protocol C4671005Final Protocol Amendment 4, 20 November 2021
PFIZER CONFIDENTIAL
Page 639.1. Statistical Hypotheses
The primary hypothesis to be tested is whether or not there is a difference in proportion of 
participants with COVID-19 related hospi[INVESTIGATOR_059] (as defined in Section 8.1.2 ) or death 
from any cause through Day 28 between PF-07321332/ritonavir and placebo. The statistical 
hypothesis is as follows:
Where πPF-[ADDRESS_360024] of the primary endpoint, sequential testing will be performed for 
the following 2 secondary endpoints:
1. Proportion of participants with COVID-19 related hospi[INVESTIGATOR_295365] 28 who did not receive COVID-19 therapeutic mAb treatment, regardless of their onset of COVID-19 related signs and symptoms.
2. Time (days) to sustained alleviation of all targeted signs/symptoms through Day 28.
Other secondary endpoints will be subsequently tested following the Hochberg procedure.
43
9.1.1. Estimands
[IP_ADDRESS]. Primary Estimand/Co-Primary EstimandsThe primary estimand is the difference in proportions of patients experiencing 
COVID-19-related hospi[INVESTIGATOR_295366] 28 in nonhospi[INVESTIGATOR_295367]-19 who are at increased risk of progression to severe disease (as defined in Section 5.1 ), who did not receive COVID-19 
therapeutic mAb treatment, and were treated ≤[ADDRESS_360025] to adherence to randomized treatment.
[IP_ADDRESS]. Secondary Estimands
The estimand associated with the key secondary efficacy objective is the difference in 
proportions of patients experiencing COVID-19-related hospi[INVESTIGATOR_295366] [ADDRESS_360026] to adherence to randomized treatment.
The estimand associated with the secondary efficacy objective regarding the duration and 
severity of signs and symptoms is the absolute difference in median time to sustained Ho:   πPF-7321332 -πplacebo =0
versus (1)
Ha:  πPF-7321332 -πplacebo്0
PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 64alleviation or resolution of sy mptoms for all nonhospi[INVESTIGATOR_295335] -19who are at increased risk of pr ogression to severe disease. This will be estimated 
irrespective of adherence to randomized treatment.
The hospi[INVESTIGATOR_059]/death rate through Day  28 is considered the main clinical outcome 
measure and signs/s ymptom duration is considered key  secondary  for this study  and so 
estimands for these measures are presented. Estimands for the other outcome measures that 
are considered supportive of the primary  outcome measures and of the sign/sy mptoms 
duration and severity  outcome measure are not presented.
9.2.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis Set Description
Full Anal ysis Set (FAS) All participants randomly  assigned to study  intervention.
Safety  Anal ysis Set 
(SAS)All participants randomly  assigned to study  intervention 
and who take at least 1 dose of study  intervention. 
Participants will be anal yzed according to the study 
intervention they  received.
Modified Intent -To-Treat 
(mITT)All participants randomly  assigned to study  intervention, 
who take a t least [ADDRESS_360027] 
1 postbaseline visit through Day  28, who at baseline did 
not receive nor were expected to receive COVID -19 
therapeutic mAb treatment, and were treated ≤3 day s after 
COVID -19 s ymptom onset. Participants wi ll be analy zed 
according to the stud y intervention to which they  were 
randomized.
Modified Intent -To-
Treat1 (mITT1)All participants randomly  assigned to study  intervention, 
who take at least [ADDRESS_360028] 
1 postbaseline visi t through Day  28 and who at baseline 
did not receive nor were expected to receive COVID -19 
therapeutic mAb treatment. Participants will be analy zed 
according to the stud y intervention to which they  were 
randomized.
Modified Intent -To-
Treat2 (mITT2)All pa rticipants randomly  assigned to study  intervention, 
who take at least [ADDRESS_360029] 1 postbaseline visit through Day  28. Participants will 
be anal yzed according to the study  intervention to which 
they were randomized.
Per-Protocol (PP) All participants in the mITT set without important protocol 
deviations considered to impact the interpretation of the 
primary  efficacy  endpoint.  Protocol deviations will be 
reviewed to generate the list of participants with significant 
deviations to be excluded from the PP analy sis set. The PP 

PF-[ADDRESS_360030] 
descriptive statistics (mean, standard deviation, minimum, and maximum), and qualitati ve 
variables will be summarized by  [CONTACT_295424]  (with the corresponding sample sizes).
For continuous endpoints, an MMRM analy sis of covariance model will be used to anal yze 
change from baseline over time. Es timated mean differences between treatments and their 
respective 95% CI and p ‑values will be calculated.
For binary  endpoints, proportion of participant with the event will be summarized for each 
group. Treatment comparison between the group will be presen ted as the difference of 
proportions with its 95% confidence interval using a similar anal ysis method as the primary  
endpoints.
For categorical endpoints, proportion of participant for each category  will be summarized for 
each group.
For count endpoints, t he total number of the events and average number of events will be 
summarized for each group. 
For time -to-event endpoints (ie, time [day s] to sustained alleviation/resolution of all targeted 
signs/sy mptoms through Day  28 and duration of each targeted COVI D‑19 sign/sy mptom), 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 662analyses will be provided: (1) a Cox proportional hazard regression model where the 
estimate of the hazard ratio for treatment (PF -07321332 vs placebo), its CI, and p‑value will 
be provided; and (2) Kaplan -Meier anal ysis where tabular summaries of the Kaplan ‑Meier 
curves providing the median, quartiles, and range will be provided for each treatment group. 
In addition, the KM curves will be presented graphically . 
Imputation of missing data within efficacy  variables and endpoints will b e computed 
according to the rules specified in the SAP. 
9.3.2. Primary Endpoint(s)/Estimand(s) Analysis
The primary  efficacy  analy sis will be conducted using the mITT population. 
The cumulative proportion of participants hospi[INVESTIGATOR_295338] -[ADDRESS_360031] 28 day s of the study  will be estimated for each treatment group using 
the Kaplan- Meier method to take account of losses to follow -up and summarized graphically  
for each treatment group. The estimand is then the difference of th e proportions in the 2 
groups and its 95% CI  will be presented, as well as, the associated Wald Test. For the 95% 
CI, the corresponding estimate of the standard error is computed using Greenwood’s 
formula.1The Greenwood’s formula to estimate the variance of the difference of proportions 
at Day  28 is [Var(S PF(28)) + Var(S Placebo (28))]. I nstead of dealing with S(t i) the log -log 
approach to CI will be used. The 95% CI will be computed for the estimate of 
L(t)= log(-log(S(t)), the log hazard function. 
The CI  will be in the right range when transformed back to S(t) = exp (- exp (L(t)). 
Antilogging this CI will give a 95% confidence interval for the difference itself. 
The above primary  analysis will be conducted for the planned interim anal ysis as well. Two-
sided 95% CI  (adjusted for the planned interim analy sis) and associated p -value for the null 
hypothesis of no difference between treatment groups will be presented. Significance level 
will be determined using the O’Brien -Fleming approach at the interim anal ysis and the final 
analysis. The overall significance level is set at 5% (2 sided). 
For participants who complete Day  28 assessment (Day  34), they  will be censored at their 
last visits. For participants who discontinue before Day [ADDRESS_360032] known date in the study .
The secondary  analy sis associated with primary  endpoint will be conducted using the mITT2 
population set. 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 67Supplemental anal yses will be performed to the primary  efficacy  endpoint:
1.Ananalysis in the mITT anal ysis set of the primary  endpoint where participants that 
received a therapeutic COVID -[ADDRESS_360033] -baseline will be considered as 
an event for the endpoint (in addition to hospi[INVESTIGATOR_53763] -19 and death due 
to any cause) with mAb treatment date as the time of event.
2.A logistic regression model will be fitted to the primary endpoint of 
hospi[INVESTIGATOR_059]/death and will include treatment and effect based on investigator site 
as independent variables (p -values will be re ported from main model). Additional 
analyses may  be performed adjusting for baseline covariates (such as age, gender, 
etc.) as additive terms to the primary  model, if necessary .
3.A completers (participants with Day  28 assessment) only  analy sis similar to th e 
primary  efficacy  anal ysis will be conducted.
9.3.3. Key Secondary Efficacy Endpoint(s)/Estimand(s) Analysis
Proportion of participants with COVID- [ADDRESS_360034] key  secondary  efficacy  endpoint is the proportion of participants with COVI D-19 
related hospi[INVESTIGATOR_295368] y cause through Day  28 in the mITT1 anal ysis set. 
The anal ysis for this endpoint is similar to the primary  endpoint, but usi ng the mI TT1 
analysis set.
Time to sustained alleviation and time to sustained resolution of targeted COVID -19 
sign/symptoms through Day 28
The key  secondary  endpoints of sustained alleviation and resolution will be defined for all 
targeted COVID -19 associated s ymptoms based on self -assessment. 
Sustained alleviation of all targeted COVID -19 signs/sy mptoms is defined as the event 
occurring on the first of [ADDRESS_360035] possible available day  
(prior to or at Day  25) to be counted as sustained alleviation/resolution. For sy mptoms with 
no reported severit y in baseline, the symptom will have to be absent in order to consider 
alleviate d/resolved (missing severity  at baseline will be treated as mild).

PF-[ADDRESS_360036] possible day  the s ymptom alleviation and resolution endpoints can be 
achieved (definition includes data from the subsequent three day s) and Day  [ADDRESS_360037] day  
partici pants report their daily  signs and s ymptoms.
The time to sustained symptom alleviation/resolution for the purpose of this study  is defined 
as: 
For a participant with sustained sy mptom alleviation/resolution (event), time to event 
will be calculated as (First Event Date) –(First Dose Date) +1.
For a participant that either completes Day  28 of the study  or discontinues from the 
study  before Day  28 without sustained sy mptom alleviation/resolution (censored), 
censoring date will be at the last date on which s ymptom alleviation/resolution is 
assessed, and time will be calculated as (Censoring Date) – (First Dose Date) +[ADDRESS_360038].
The decision to require 4 consecutive day s with all targeted s ymptoms absent was based on 
exploratory  anal yses of data from the ACTIV -2/A5401 study , which suggested that this 
choice (rather than requiring fewer consecutive days) better captured sustained sy mptom 
resolution with low probability  of subsequent relapse. 
Participants who are hospi[INVESTIGATOR_295369] -19 or die from any  cause 
during the 28 -day period will be classified as not achieving sustained sy mptom 
alleviation/resolution and will be censored at day  25.
Cox proportional hazard model anal yses will be used for time to sustained sy mptom
alleviation/resolution.
Time to sustained sy mptom alleviation/resolution will be summarized graphically  using 
Kaplan -Meier plots for each of the treatment groups, the anal yses will be done using mITT 
population, mI TT1 population, and the mITT2 population.
9.3.4. Secondary Endpoint(s)/Estimand(s) Analyses
Proportion of participants with severe signs/sy mptoms attributed to COVID -19 
through Day  28
Duration of each targeted COVID -19 sign/sy mptom
Progression to a worsening status in 1 or more self -reported COVID -19 as sociated 
symptoms through Day  28
Proportion of participants with a resting peripheral oxy gen saturation ≥95% at Day s 1 
and 5. 
Proportion of participants with death (all cause) through Week 24

PF-07321332
Protocol C4671005Final Protocol Amendment 4, 20 November 2021
PFIZER CONFIDENTIAL
Page 69•PK of PF-07321332 
•Viral titers (RT-PCR) measured in nasal swabs over time
•Number of COVID-19 related medical visits through Day 28.
•Number of days in hospi[INVESTIGATOR_295370]-19 related 
hospi[INVESTIGATOR_059].
Details on the definitions and analyses of secondary endpoints will be described in the SAP.
9.3.6. Other Safety Analyses
Safety analyses will be carried out for the Safety population.  
The safety assessments include AEs, laboratory assessments, physical examinations, and 
vital signs. No formal statistical analysis will be conducted on any of the other safety data listed above.
[IP_ADDRESS]. Laboratory
All clinical laboratory data will be subjected to clinical review, summarized by [CONTACT_295425].
[IP_ADDRESS]. Physical Examination and Vital Signs
All physical examination and vitals will be descriptively summarized by [CONTACT_1570]. 
 
 
Long-term COVID-19 symptoms will be collected by [CONTACT_295426] 12 and 
24 and PRO data (Global impression questions, EQ-5D-5L, WPAI) will be collected during the trial. These data are not planned to be included in the CSR.
[IP_ADDRESS]. PK Analyses 
Descriptive statistics and graphical summaries of PF-07321332 concentrations will be 
generated. PK samples will be collected as described in the SoA. Additional PK sampling 
may be collected in a subset of participants via home health, site visit, or self-collected using Tasso, if feasible. Ritonavir concentrations may also be reported. PK data from this study may be combined with other studies and analyzed using population PK approaches. Results from any population PK analyses will be reported outside of the clinical study report.CCI
CCI
PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 709.4.Interim Analyses
A planned interim anal ysis for efficacy  and futility with a sample size -re-estimation will be 
conducted and reviewed by  [CONTACT_10981] E- DMC after approximately  45% overall 
participants have completed the Day  28 assessments in the mI TT anal ysis set (ie , 28 day s 
after randomization). 
At the time of planning the Phase 2/[ADDRESS_360039] of PF
-07321332. Hence, a sample size re -estimation will be conducted 
during the interim anal ysis based on conditional power. The sample s ize can be adjusted one 
time and the increase will be capped at 30%. A well- established method described b y Cui, 
Hung, and Wang (1999)44(implemented in EAST 6.5) will be used to control the Ty pe I 
error probability .45
The nominal significance level for the planned interim and final proportion of 
hospi[INVESTIGATOR_059]/death analy ses is determined by  [CONTACT_295427] -DeMets procedure with an 
O’Brien -Fleming stoppi[INVESTIGATOR_3106], with an overall 2- sided ty pe I error rate of 5%.
For the interim anal ysis (45%), O’Brien -Fleming approach will be used for decision mak ing, 
ie, reject H 0with 2 -sided p -value ≤0.002, or reject H1 with 2- sided p- value >0.924. The final 
p-value for rejecting H 0will be ≤0.049 (2 -sided) or reject H1 with 2- sided p -value >0.049. 
The actual stoppi[INVESTIGATOR_295371] o f the interim analy sis.If the 
efficacy  boundary  is crossed at the interim anal ysis, a final anal ysis will be conducted as a 
supportive anal ysis.
Before an y interim anal ysis is performed, the details of the objectives, decision criteria, 
dissemination plan, and method of maintaining the study  blind as per [COMPANY_007]’s SOPs will be 
documented and approved in an E- DMC C harter. In addition, the anal ysis details will be 
documented and approved in the SAP.
9.5.Sample Size Determination
The estimate of required sample size is based on data from the BLAZE -1 Phase 2/3 trial 
among participants with mild to moderate COVID -19 who were at high risk for progressing 
to severe COVID -19 and/or hospi[INVESTIGATOR_295339].2During the 29- day period 
following enrollment, the proportion of placebo -treated participants with a 
COVID -19-related hospi[INVESTIGATOR_059]/emergency  department visit was 7% in the Phase [ADDRESS_360040] 90% statistical power to show a difference of 3.5% in the 
proportion of participants hospi[INVESTIGATOR_057]/ dying that did not receive COVID -19 therapeutic mAb 
between the treatment arms (PF -07321332/ritonavir versus placebo) and were treated 
≤3days after COVID -19 sy mptom onset, using a 2 -sided Ty pe I error rate of 5%. Based on 
the above stud y,3the proportion of hospi[INVESTIGATOR_059]/death in the placebo arm is assumed to be 
7%. 

PF-[ADDRESS_360041] (Version 6.5) for a [ADDRESS_360042] 
this difference w ith 90% power at a 2 -sided significance level of 5% was determined to be 
[ADDRESS_360043] received/expected to 
receive COVID -19 therapeutic mAb treatment is expected to be approximately  20% and will 
be limi ted to approximately  25% of participants. Enrollment of participants that had 
COVID -19 s ymptom onset >3 day s prior to randomization is expected to be approximately  
25% and will be limited to a total of approximately  1000 participants. Assuming a 5% 
dropout rate, the total sample size for this study  will be approximately  3000 participants. 
Study  enrollment will be stopped after approximately  1717 participants are available for the 
primary  anal ysis.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 7210.SUPPORTING DOCUMENTATION AND OPERATIONAL CO NSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from internatio nal guidelines, including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines;
Applicable ICH GCP guidelines;
Applicable laws and regulations, including applicable privacy  laws.
The protocol, protocol amendments, I CD, SRSD(s), and other relevant documents (eg, 
advertisements) must be reviewed and approved by [CONTACT_456], submitted to an I RB/EC by  
[CONTACT_093], and reviewed and approved b y the I RB/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC appr oval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to in itiation except for changes necessary  to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adhere nce to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regul ations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, [COMPANY_007] should be informed immediately . 

PF-[ADDRESS_360044], and 
of an y serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and sub- investigators will provi de the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for p roviding information on financial interests during the 
course of the stud y and for 1 y ear after completion of the study .
10.1.3. Informed Consent Process 
The investigator or his/her representative will explain the nature of the study, including the 
risks and bene fits, to the participant or his/her legally  authorized representative and answer 
all questions regarding the study . The participant or his/her legall y authorized representative 
should be given sufficient time and opportunity  to ask questions and to decide whether or not 
to participate in the trial.
Participants must be informed that their participation is voluntary . Participants or their 
legally  authorized representative will be required to sign a statement of informed consent that 
meets the requirements of 21 CFR 50, local regulations, I CH guidelines, privacy  and data 
protection requirements, where applicable, and the I RB/EC or study  center.
The investigator must ensure that each study  participant or his or her legally  authorized 
representative is fully  informed about the nature and objectives of the study , the sharing of 
data related to the study , and possible risks associated with participation, including the risks 
associated with the processing of the participant’s personal data. 
The participant or his o r her legall y authorized representative must be informed that his/her 
personal stud y-related data will be used by  [CONTACT_78271]. The level of disclosure must also be explained to the participant or his or her 
legally authorized representative.
The participant or his or her legall y authorized representative must be informed that his/her 
medical records may  be examined by  [CONTACT_78272] b y the sponsor, b y appropriate I RB/EC members, and by  [CONTACT_78273].
The investigator further must ensure that each study  participant or his or her legall y 
authorized representative is fully  informed about his or her right to access and correct his or
her personal data and to withdraw consent for the processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date on which the wri tten consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.

PF-[ADDRESS_360045] 
current version of the ICD(s) during their participation in the study .
A cop y of the ICD(s) must be provided to the participant or the participant’s legall y 
authorized representative.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic form and 
will be password- protected to ensure that only authorized study  staff have access. The study  
site will implement appropriate technical and organizational measures to ensure that the 
personal data can be recovered in the event of disaster. In the event of a potential personal 
data breach, the stud y site will be responsible for determining whether a person al data breach 
has in fact occurred and, if so, providing breach notifications as required by [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specif ic numerical code. Any  
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007] , participant -specific code. The study  site will 
maintain a confidential list of participants who participated in the study , linking each 
participant’s numerical code to his or her actual identity  and medical record ID. In case of 
data transfer, the sponso r will protect the confidentiality  of participants’ personal data 
consistent with the clinical study  agreement and applicable privacy  laws.
10.1.5. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee 
This study  will use a n E-DMC. The E -DMC is independent of the stud y team and includes 
only external members. The E- DMC charter describes the role of the E -DMC in more detail.
The E-DMC will be responsible for ongoing monitoring of the efficacy  and safet y of 
participants in the study  according to the charter. The recommendations made by  [CONTACT_941] E -DMC 
will be forwarded to the appropriate authorized [COMPANY_007] personnel for review and final 
decision. [COMPANY_007] will communicate such decisions, which may  include summaries of 
aggregate anal yses of safety  data to regulatory  authorities, investigators, as appropriate. 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 75The E- DMC will review unblinded data to ensure the safet y of participants on an ongoing 
basis throughout the duration of the study, as specified in the E -DMC Charter. In addition to 
up to weekl y reviews of safet y, the E -DMC will review the following:
Sentinel cohort safet y review : The E -DMC will review unblinded safet y data after 
approximately  the first [ADDRESS_360046] completed Day  10 of the stud y, at which 
point enrollment will be paused pending E -DMC review of the safety data. After 
review of the sentinel cohort, the frequency  of safety  reviews may  be reduced 
subsequently  based on E -DMC recommendations.
Proof -of-concept assessment : The E -DMC will review viral load data when 
approximately  200 participants in the primary  analy sis set with evaluable data 
complete the Day  5assessments. Enrollment will not be paused during review of 
these data but may  be paused or stopped following E -DMC review.
Interim anal ysis: A planned interim a nalysis for efficacy  and futility  with a sample 
size re -estimation will be done after approximately  45% of participants in the mITT 
set complete the Day  28 assessments (ie, 28 day s after randomization). 
The E- DMC will also review the results of planned in terim analy sis. Efficacy  data will be 
available to the E -DMC for the interim anal ysis. Details of the E -DMC are specified in the 
E-DMC Charter.
The E- DMC will review all deaths that occur during the study . A pause in enrollment 
pending E -DMC review will oc cur if 2 participants experience a Grade 4 or higher AE that is 
deemed related to study intervention as determined by [CONTACT_295428].
10.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and ar e reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007] -sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These results are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].

PF-[ADDRESS_360047] for [COMPANY_007]- sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results are 
posted to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy , includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the prot ocol and protocol 
amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this 
policy , includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centr alized procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July  2015.
Data sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for th e purposes 
of “bona -fide scientific research” that contributes to the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make data from these trials available 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Researc h teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.7. Data Quality Assurance
All participant data relati ng to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.

PF-[ADDRESS_360048] permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details d escribing strategy , including definition of study  critical data items and 
processes (eg, risk- based initiatives in operations and quality  such as risk management and 
mitigation strategies and anal ytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on -site monitoring), are provided in the data management plan and 
monitoring plan maintained and utilized by  [CONTACT_36613].
The sponsor or designee is responsible for the data management of this study , including 
quality  checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for [ADDRESS_360049] ensure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_295372] e promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify the sponsor or its agents immediately  of any  regulatory  retain  
notification in relation to the study . Furthermore, the investigator will cooperate with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow the 
sponsor or its agent, whenever feasible, to be present during the inspection. The investigator 
site and investigator will promptly  resolve an y discrepancies that are identified between the 
study  data and the participant's medical records. The investigator will promptly  provide 
copi[INVESTIGATOR_19946]. Before response submission to 
the regulatory  authorities, the investigator will provide the sponsor or its agents with an 
opportunity  to review and comment on responses to any  such findings.

PF-[ADDRESS_360050] maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will perform ong oing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being c onducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time fo r any reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/CRO if requested to do so by  [CONTACT_51025] I RB/EC or if such termination is 
required to protect the health of study  participants.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 79Reasons for the ea rly closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines;
Inadequ ate recruitment of participants by  [CONTACT_093]; 
Discontinuation of further study  intervention development.
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO(s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate participant therap y and/ or follow -
up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.10. Publication Policy
The results of this study  may  be p ublished or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1 y ear after the end of the study  
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications, 
such as secondary  manuscripts, and submits all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments, and the investigator will, on request, remove an y previously undisclosed 
confidential information before disclosure, except for an y stud y
-or [COMPANY_007] 
intervention -related information necessary  for the appropriate scientific presentation or 
understanding of the study  results.
For al l publications relating to the study , the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for publication of the overall study  results 
covering all investigator sites. I n accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
indivi dual site data. I n this case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Ed itors authorship 
requirements. 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 80If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.11. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately  qualif ied medical personnel for the 
study  is documented in the study  contact [CONTACT_20015]/study  portal or other electronic s ystem. 
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participants are provided with an Emergency  Contact [CONTACT_74057] (ECC) at 
the time of informed consent. The ECC contains, at a minimum, (a) protocol and study  
intervention identifiers, (b) participant’s stud y identification number, (c) site emergency  
phone number active 24 hours/day , 7 day s per week, and (d) [COMPANY_007] Call Center number.
The ECC is intended to augment, not replace, the established communication pathway s 
between the investigator, site staff, and study  team. The ECC is to be used by [CONTACT_78277] y only , as a means of reaching the investigator 
or site staff related to the care of a participant. The [COMPANY_007] Call Center number should only  be 
used when the investigator and site staff cannot be reached. The [COMPANY_007] Call Center number is 
not intended for use b y the participant directly ; if a participant calls that number directl y, he 
or she will be directed back to the investigator site.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 8110.2. Appendix 2: Clinical Laboratory Tests
The fol lowing safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory  results may  be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by [CONTACT_20019] , or as derived 
from calculated values. These additional tests would not require additional collection of 
blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during the 
study  to assess an y perceived saf ety issues
Table 1. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Other Additional Tests 
(Needed for Hy’s Law)
Hem oglobin
Hem atocrit
RBC count
Platelet count
WBC count
Total neutrophils 
(Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN or urea
Creatinine a
Glucose
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
Albumin
Total proteinFerritin
hsCRP
Procalcitonin
LDH
CK
Haptoglobin
Thyroid function
TSH
T4 (free)
Coagulation 
PT/aPTT
Fibrinogen
D-dimer
SARS -CoV- 2 
serology (IgM, IgG)
FSHb
Pregnancy test 
(β-hCG)cAST, ALT (repeat)
Total bilirubin (repeat)
Albumin 
Alkaline phosphatase 
(repeat)
Direct bilirubin
Indirect bilirubin
Creatine kinase
GGT
PT/INR
Total bile acids
Acetaminophen drug 
and/or protein adduct 
levels
a.eGFR will be calculated using the method developed by [CONTACT_91019] -EPI [INVESTIGATOR_295373].[ADDRESS_360051] for the protocol unless serum testing is required by [CONTACT_216483]/EC. Serum or urine -hCG for female participants of childbearing potential.
The investigator must review the laboratory  report, document this review, and record an y 
clinically  relevant changes occurring during the study  in the AE section of the CRF.  

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 8210.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and uninte nded sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator. An y abnormal laboratory  test 
results that meet an y of the conditions below must be recorded as an AE:
Is associated with accompany ing s ymptoms.
Requires additional diagnostic testing or medical/surgical intervention.
Leads to a change in study  dosing (outside of an y protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either an 
increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration, even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 83Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
An SAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of t he criteria listed below:
a.Results in death
b.Is life -threatening
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event that 
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_12994] (usually  
involving at least an overn ight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_295374], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the 
AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did n ot worsen 
from baseline is not considered an AE.
d.Results in persistent or significant disability/incapacity

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 84The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), that may  interfere with or 
prevent every day life functions but do not constitut e a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic 
or non- pathogenic, is considered serious.  
The event may  be suspected from clinical s ymptoms or laborato ry findings indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “suspected 
transmission” and “transmission” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigil ance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by  [CONTACT_78278], such as significant 
medical events that may jeopardize the participant or may  require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.

PF-[ADDRESS_360052] ing/Reporting and Follow -Up of AEs and/or SAEs During the Active 
Collection Period 
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safet y throughout the active 
collection period. These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 
nonserious AEs; and (3) exposure to the study  intervention under stud y during pregnancy  
or breastfee ding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must be 
completed in a consistent manner. AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours 
of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding, All AEs or SAEs 
associated with exposure 
during pregnancy  or 
breastfeeding
Note:   Instances of EDP or 
EDB not associated with an 
AE or SAE are not 
captured in the CRF.All instances of EDP are 
reported (whether or not 
there is an associated 
SAE) *
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE). **
Environmental or 
occupational exposure to 
the product under stud y to 
a non -participant (not 
involving EDP or EDB).None.  Exposure to a study  
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported. ***

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 86*EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
[COMPANY_007] Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Report 
Form . 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form which w ould also include 
details of any SAE that might be associated w ith the EDB. 
***Environmental or Occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to [COMPANY_007] Safety using the CT SAE Report Form. 
When an AE or SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety in lieu of completion of the CT SAE Report 
Form/AE or SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories, which are based on the 
Division of AIDS (DAIDS) Table for Grading the S everity  of Adult and Pediatric Adverse 
Events,42version 2.1 (July 2017):
GRADE Clinica l Description of Severity
1 MILD adverse event
2 MODERATE adverse event
3 SEVERE adverse event
4 POTENTIALLY LIFE -THREATENING event 
5 DEATH RELATED TO adverse event
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 87Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
Alternative causes, suc h as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product i nformation, for marketed 
products, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be situations in which an SAE ha s occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE d ata to the sponsor.
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining reg ulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention” for reporting 
purposes, as defined b y the sponsor. In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this 
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accor dance 
with the SAE reporting requirements.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 88Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  [CONTACT_103], to elucidate the nature and/or causalit y of the AE or SAE as full y as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers.
If a participant dies during parti cipation in the study  or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings, including histopathology .
New or updated information will be recorded in the originally  submitted 
documents.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety  will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) to report the event within 24 hours.
The site will enter the SAE data into the electro nic sy stem as soon as the data 
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_162520].

PF-[ADDRESS_360053] SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working, notification b y telephone is 
acceptable with a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designat ed reporting 
time frames.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 9010.4. Appendix 4: Contraceptive and Barrier Guidance 
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for a t least [ADDRESS_360054] dose of stud y intervention, which
corresponds to the time needed to eliminate reproductive safet y risk of the study  
intervention(s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent. 
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom when having sexual intercourse with a woman of 
childbearing potential who is not currently  pregnant.
In addition to male condom use, a highl y effective method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly  
effect ive methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least [ADDRESS_360055] ies:
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly  effective (with a 
failure rate of <1% per year), as described below, during the intervention period 
and for at least [ADDRESS_360056] dose of stud y intervention, which 
corresponds to the time needed to eliminate an y reproductive safety  risk of the 
study  intervention(s). If a highl y effective method that is user dependent is 
chosen, 
a second effective method of contraception, as described below, must also
be used. The investigator should evaluate the effectiveness of the contraceptive 
method in relationship to the first dose of stud y intervention. 

PF-[ADDRESS_360057] 
also be used if the participant is using estradiol -containing contraceptives.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decreas e the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following: 
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insen sitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history  
interview. The method of documentation should be recorded in the participant’s medical 
record for the stud y.
2.Postmenopausal female:
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.  I n addition:
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 50 years of age and not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highl y effective contraception methods 
if they  wish to continue their HRT during the study . Otherwise, they  must 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 92discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contraception Methods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4. Bilateral tubal occlusion (eg, bilateral tubal ligation).
5.Vasectomized partner:
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sol e sexual partner of the woman of childbearing potential and 
the absence of sperm has been confirmed. If not, an additional highl y effective 
method of contraception should be used. The spermatogenesis cy cle is 
approximately  90 day s.
6.Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation:
Oral;
Intravaginal;
Transdermal.
7.Progestogen -only hormone contraception associated with inhibition of ovulation:
Oral;
Injectable.
8.Sexual abstinence:
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the durat ion of the study  and the preferred and usual 
lifesty le of the participant.

PF-[ADDRESS_360058] also be used when 
option 6 or 7 are chosen above:
Male or female condom with or without spermicide;
Cervical cap, di aphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).
Because ritonavir may  reduce the effect of estradiol- containing contraceptives when agents 
are coadmin
istered, a barrier method or other nonhormonal method of contraception must 
also be used if the participant is using estradiol -containing contraceptives.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 9410.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, 
susceptibility  to, and severity  and progression of disease. Therefore, where local 
regulations and IRBs/ECs allow, a blood sample will be collected for DNA anal ysis.
The scope of the genetic research may be nar row (eg, 1 or more candidate genes) or 
broad (eg, the entire genome), as appropriate to the scientific question under 
investigation.
The samples may  be analy zed as part of a multistudy  assessment of genetic factors 
involved in the response to study  interve ntion or study  interventions of this class to 
understand treatments for the disease(s) under study  or the disease(s) themselves.
The results of genetic analy ses may  be reported in CSR or in a separate study  
summary , or may  be used for internal decision making without being included in a 
study  report.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained as indicated:
Retained samples will be stored indefinitely  or fo r another period as per local 
requirements.
Participants may  withdraw their consent for the storage and/or use of their Retained 
Research Samples at an y time by  [CONTACT_7328] a request to the investigator; in this case, 
any remaining material will be destroy ed. Data already  generated from the samples 
will be retained to protect the integrit y of existing anal yses.
Samples for genetic research will be labeled with a code. The key  between the code 
and the participant’s personally  identify ing information (eg, name, address) will be 
held securely  at the study site.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 9510.6. Appendix 6: Liver Safety: Suggested Actions and Follow -Up Assessments and 
Study Intervention Rechallenge Guidelines
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more seri ous potential outcome. These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI. 
Participants who experience a transaminase elevation above 3 ×ULN should be monitored 
more freq uently  to determine if they  are “adaptors” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations (>2 ×
ULN) b y several days or weeks. The increase in TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are 
still ele vated above 3 × ULN (ie, AST/ALT and TBili values will be elevated within the same 
laboratory  sample). In rare instances, by  [CONTACT_22858], AST/ALT 
values might have decreased. This occurrence is still regarded as a potential DILI. Therefore, 
abnormal elevations in either AST OR ALT in addition to TBili that meet the criteria 
outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases and 
should alway s be considered important medical events, even before all o ther possible causes 
of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions. Participants who present 
with the following labo ratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently  prese nt with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participants with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whiche ver is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-[ADDRESS_360059]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_360060] and AL T and TBili for suspected Hy’s law 
cases, additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separat e tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by  [CONTACT_20025] a coformulated 
product in prescription or over -the-counter medications) , recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel hist ory, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection, liver imaging (eg, biliary  tract), and collection of serum 
samples for acetaminophen /paracetamol drug and/or protein adduct levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 9710.7. Appendix 7:ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as AEs
Marked sinus brady cardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 msec.
New prolongation of QTcF to >480 msec (absolute) or by60msec from baseline.
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate <120 bpm.
New -onset ty peI second -degree (Wenckebach) AV block of >30 seconds’ 
duration.
Frequent PVCs, triplets, or short intervals (<30 seconds) of consecutive ventricular 
complexes.
ECG Findings That May Qualify as SAEs
QTcF prolongation >500 msec.
New ST -Tchanges suggestive of myocardial ischemia.
New -onset left bundle branch block (QRS >120 msec).
New -onset right bundle branch block (QRS >120 msec).
Symptomatic brady cardia. 
Asystole:
In awake, s ymptom -free patients in sinus rhy thm, with documented periods of 
asystole ≥3.0 seconds or any  escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node; 
In awake, s ymptom -free patients wi th atrial fibrillation and brad ycardia with [ADDRESS_360061] 5 seconds or longer; 
Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained supraventricular tach ycardia (rate >120 bpm) (“sustained” = short 
duration with relevant symptoms or lasting >1 minute).

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL
Page 98Ventricular rh ythms >30 seconds’ duration, including idioventricular rhy thm (heart 
rate <40 bpm), accelerated idioventricular rh ythm (HR 40 bpm to <100 bpm), and 
monomorphic/poly morphic ventric ular tach ycardia (HR >100 bpm (such as 
torsades de pointes)).
Type IIsecond -degree (Mobitz II) AVblock.
Complete (third- degree) heart block.
ECG Findings That Qualify as SAEs
Change in pattern suggestive of new m yocardial infarction. 
Sustained ventricular tachy arrhy thmias (>30 seconds’ duration).
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.
Ventricular fibrillation/flutter.
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience.
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and [COMPANY_007] study team, and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 9910.8. Appendix 8: Prohibited Concomitant Medications That May Result in DDI  
PF-07321332 and ritonavir are both primarily  metabolized by  [CONTACT_097]3A4. Therefore, 
concomitant use of an y medications or substances that are strong inducers of CYP3A4 are 
prohibited within 28 days prior to dosing of stud y intervention and during study  treatment. 
Additionally , ritonavir and PF -07321332 are inhibitors of CYP3A4. Therefore, medications 
highl y dependent on CYP3A4 for clearance and for which elevated plasma concentrations 
may be associated with serious and/or life
-threatening events are not permitted during dosing 
of PF -07321332/ritonav ir (at least [ADDRESS_360062] dose of study  intervention –see below) and for [ADDRESS_360063] dose of PF -07321332/ritonavir. Ritonavir also appears to induce CYP3A, CYP1A2,
CYP2C9, CYP2C19, and CYP2B6 as well as other enzy mes, including glucuronos yl 
transferase. Since ritonavir [ADDRESS_360064] of drugs prohibited for potential DDI concerns with the IMP may  be revised during 
the course of the study  with written notification from sponsor, to include or exclude specific 
drugs or drug categories for various reasons (eg, emerging DDI results for the IMP, 
availability  of new information in literature on the DDI potential of other drugs).   
This is not an all -inclusive list. Site staff should consult with the sponsor or designee with 
any questions regarding potential DDI.

PF-[ADDRESS_360065] not use these medications within 28 days 
prior to randomization and during dosing of PF -07321332/placebo and ritonavir/placebo. 
Drug Class Specific Medication Clinical Comments 
Anti-infectives Rifampin Reduced concentrations of PF -
07321332/ritonavir; may result in 
suboptimal concentrations Anticonvulsants Phenytoin, Carbamazepi[INVESTIGATOR_295375]. John’s Wort 
Prohibited Medications Dependent on CYP450 3A4 for Clearance or with other Notable 
Interactionsa 
These medications are prohibited for at least [ADDRESS_360066] dose of PF -0321332/placebo 
and ritonavir/placebo, through [ADDRESS_360067] dose of PF -07321332/placebo and ritonavir/placebo. 
If a participant cannot temporarily interrupt the prohibited medication during this period, they should be 
considered ineligible.  
Drug Class Specific Medication Clinical Comments 
Alpha [ADDRESS_360068] Alfuzosin Risk of hypotension, syncope 
Analgesics Pi[INVESTIGATOR_18234], propoxyphene Analgesic concentrations may 
increase 
Antianginal Ranolazine Risk of cardiac arrhythmias  
Antiarrhythmics   Dronedarone Risk of cardiac arrhythmias  
Antipsychotics clozapi[INVESTIGATOR_050], lurasidone, pi[INVESTIGATOR_295376]. 
Ergot Derivatives  Dihydroergotamine, ergotamine, 
methylergonovine Risk of acute ergot toxicity 
(peripheral vasospasm and 
ischemia of the extremities) 
Lipid low ering drugs 
(HMG -CoA Reductase 
Inhibitors)  Lovastatin, simvastatin Risk of rhabdomyolysis 
PDE -5 Inhibitors for 
pulmonary arterial 
hypertension treatment Sildenafil (Revatio) when used for 
pulmonary arterial hypertension Risk of visual disturbances,  
Co-administration may result in 
visual abnormalities, 
hypotension, prolonged erection, 
and syncope 
Sedatives/ 
Hypnotics Triazolam, oral midazolam  Risk of prolonged sedation, 
respi[INVESTIGATOR_2341], or 
hypnotic concentrations 
Miscellaneous Drugs  Colchicine Ritonavir 100 mg twice daily 
increased colchicine AUC 296% 
and C max184%.  Potential for 
serious and/or life -threatening 
reactions in patients with renal 
and/or hepatic impairment.  
a. Note: If a drug is not listed, it should not automatically be assumed it is safe to co -administer. 

PF-[ADDRESS_360069] dose of PF -0321332/placebo and ritonavir/placebo, through 
4days after the last dose of PF -07321332/placebo and ritonavir/placebo. If a participant cannot temporarily 
interrupt the prohibited medication during this period, they should be considered ineligible.   
Drug Class Specific Medication Clinical Comments 
Alpha [ADDRESS_360070] Tamsulosin, silodosin, doxazosin 
(>2mg daily), terazosin (>5 mg 
daily), Risk of hypotension, syncope 
Analgesics 
Opi[INVESTIGATOR_295377], oxycodone 
Buprenorphine 
Lofexidine 
Pethidine (Meperidine) Moderate to w eak decreases in 
methadone concentrations have 
been observed 
Analgesic concentrations may 
increase 
Co-administration may increase 
concentrations of buprenorphine 
and lofexidine 
Co-administration with ritonavir 
may result in increase in 
concentration of the metabolite 
norm eperidine 
Antiarrhythmics   Amiodarone, Bepridil, Flecainide, 
Propafenone, Quinidine, Encainide, 
Disopyramide, dofetilide, lidocaine, 
mexiletine  Risk of car diac arrhythmias   
Anticoagulants/ 
antiplatelet  Rivaroxaban, Vorapaxar, api[INVESTIGATOR_3822], 
betrixaban, dabigatran, edoxaban   
ticagrelor 
Warfarin Possible increased risk of 
bleeding 
Possible decreased w arfarin 
effects 
Anticonvulsants Ethosuximide 
Eslicarbazepi[INVESTIGATOR_295378]-administration may increase 
these anticonvulsant 
concentrations or decrease 
PF-[ADDRESS_360071] dose of PF -0321332/placebo and ritonavir/placebo, through 
4days after the last dose of PF -07321332/placebo and ritonavir/placebo. If a participant cannot temporarily 
interrupt the prohibited medication during this period, they should be considered ineligible.   
Drug Class Specific Medication Clinical Comments 
Antidepressant Desipramine, Fluoxetine, 
Paroxetine 
nefazodone, Amoxapi[INVESTIGATOR_050], 
Clomipramine, Doxepin, Imipramine, 
Maprotiline 
Amitryptiline, nortryptiline, 
protryptiline, Trimipramine,  
aripi[INVESTIGATOR_295379]-infective (antibacterials) Erythromycin Co-administration may increase 
erythromycin concentrations. 
Clarithromycin Co-administration may increase 
clarithromycin concentrations. 
(antimycobacterials)  Bedaquiline Co-administration may increase 
bedaquiline concentrations 
Rifabutin Co-administration may increase 
rifabutin concentrations  
(antifungals) Isavuconazole 
Itraconazole 
Posaconazole 
Ketoconazole 
Voriconazole Possible increased 
concentrations of antifungal, of 
PF-07321332, or both.  
Co-administration of ritonavir 
with voriconazole may result in 
reduction in voriconazole levels 
Antihistamines Astemizole, Terfenadine Risk of cardiac arrhythmias 
Antipsychotics Quetiapi[INVESTIGATOR_295380], Perphenazine, 
aripi[INVESTIGATOR_4253], brexpi[INVESTIGATOR_4253], 
cariprazine, Iloperidone, 
perphenazine, risperidone, 
thioridazine, ziprasidone Co-administration may increase 
quetiapi[INVESTIGATOR_295381].  
Potential for increased levels of 
antipsychotics. 
Cardiac Medications 
(beta blockers) Carvedilol, metoprolol, timolol Co-administration may increase 
concentration of carvedilol, 
metoprolol, timolol 

PF-[ADDRESS_360072] dose of PF -0321332/placebo and ritonavir/placebo, through 
4days after the last dose of PF -07321332/placebo and ritonavir/placebo. If a participant cannot temporarily 
interrupt the prohibited medication during this period, they should be considered ineligible.   
Drug Class Specific Medication Clinical Comments 
(calcium channel blockers)  Diltiazem, Verapamil,  
Nifedipi[INVESTIGATOR_050], amlodipi[INVESTIGATOR_050] (> 5 mg 
daily) Co-administration may increase 
concentrations of calcium 
channel blockers. The impact on 
the PR interval of co -
administration of ritonavir with 
other drugs that prolong the PR 
interval (including calcium 
channel blockers) has not been 
evaluated.  
(cardia c glycosides) Digoxin Co-administration increases 
digoxin concentrations. 
Eplerenone Co-administration increases 
eplerenone concentrations 
Ranolazine Co-administration increases 
ranolazine concentrations 
Ivabradine Co-administration increases 
ivabradine concentrations 
Corticosteroids 
(inhaled or intranasal) 
(systemic) 
(Local injections, including intra -
articular, epi[INVESTIGATOR_13873], or intra- orbital) Budesonide,  
ciclesonide,  
mometasone  
Betam ethasone 
Budesonide 
Betam ethasone, methylprednisolone, 
triamcinolone Co-administration can increase 
concentration of budesonide, 
ciclesonide, and mometasone 
and can result in adrenal 
insufficiency and Cushing’s 
syndrome. 
Co-administration can increase 
concen tration of betamethasone, 
and budesonide and can result 
in adrenal insufficiency and 
Cushing’s syndrome. 
Co-administration can increase 
betamethasone, 
methylprednisolone, and 
triamcinolone concentrations 
and can result in adrenal 
insufficiency and Cushin g’s 
syndrome 
Endothelin receptor antagonists Bosentan Bosentan should be 
discontinued at least [ADDRESS_360073] dose of PF -0321332/placebo and ritonavir/placebo, through 
4days after the last dose of PF -07321332/placebo and ritonavir/placebo. If a participant cannot temporarily 
interrupt the prohibited medication during this period, they should be considered ineligible.   
Drug Class Specific Medication Clinical Comments 
Ergot Derivatives Ergonovine Risk of acute ergot toxicity 
(peripheral vasospasm and 
ischemia of the extremities) 
Hepatitis C direct acting antivirals 
(DAAs) Boceprevir, Glecaprevir/Pi[INVESTIGATOR_295382], 
Sofosbuvir/Velpatasvir/Voxilaprevir, 
Ombitasvir/Paritaprevir/ritonavir/ 
Dasabuvir, Grazoprevir/elbasvir Co-administration can increase 
plasma concentrations of select 
DAAs  
  
HIV Antiretrovirals 
Protease Inhibitors 
Integrase Inhibitors Lopi[INVESTIGATOR_054], Amprenavir, Indinavir, 
Nelfinavir, Atazanavir, Darunavir, 
fosamprenavir, saquinavir, 
tipranavir. 
Ritonavir or cobicistat containing 
combination products 
Elvitegravir Co-administration may increase 
HIV protease inhibitor 
concentrations. 
Risk of increased rate of 
adverse reactions. Appropriate 
doses of additional ritonavir in 
combination with 
ritonavir -containing 
combination products with 
respect to safety and efficacy 
have not been established. 
Co-administration will increase 
elvitegravir concentrations 
Lipid low ering drugs 
(HMG -CoA Reductase 
Inhibitors) Atorvastatin (>20 mg daily), 
Rosuvastatin (>10 mg daily) 
Lomitapi[INVESTIGATOR_295383]-administration may increase 
concentration of lomitapi[INVESTIGATOR_295384], Tolbutamide 
Repaglinide 
Saxagliptin (>2.5 mg daily) Potentially decrease glipi[INVESTIGATOR_295385]-administration may increase 
saxagliptin concentration 
Immunosuppressants Cyclosporine, Tacrolimus, 
Sirolimus, everolimus Co-administr ation may increase 
immunosuppressant 
concentrations  

PF-[ADDRESS_360074] dose of PF -0321332/placebo and ritonavir/placebo, through 
4days after the last dose of PF -07321332/placebo and ritonavir/placebo. If a participant cannot temporarily 
interrupt the prohibited medication during this period, they should be considered ineligible.   
Drug Class Specific Medication Clinical Comments 
Long -Acting Beta -
Adrenoceptor Agonist Salmeterol The combination may result in 
increased concentrations of 
salmeterol and increased risk of 
cardiovascular adverse events, 
including QT prolongation, 
palpi[INVESTIGATOR_295386]/ Hypnotics Midazolam (parenteral), alprazolam, 
brom azepam, brotizolam, 
clonazepam, cloniprazepam, 
delorazepam, diazepam, etizolam, 
eszopi[INVESTIGATOR_11123], halazepam, 
lormetazepam, nitrazepam, 
nordiazpam, quazepam, suvorexant, 
temazepam, zaleplon, zolpi[INVESTIGATOR_295387], estazolam, flurazepam, 
Zolpi[INVESTIGATOR_6730] (> 5mg daily) Risk of prolonged sedation, 
respi[INVESTIGATOR_2341], or 
hypnotic concentrations 
Co-administration with ritonavir 
may increase dose of 
clorazepate, estazolam, and 
flurazepam. 
Co-administration may increase 
zolpi[INVESTIGATOR_295388] (>75 mg twice daily) 
Flibanserin Co-administration may result in 
increased cisapride
concentration and possible  
cardiac arrhythmias 
Co-administration may increase 
dronabinol concentration 
Co-administration may increase 
eluxadoline concentration 
Co-administration may increase 
flibanserin concentration.  
a. Note: If a drug is not listed, it should not automatically be assumed it is safe to co-administer. 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 106Hormonal Contraceptives: Estradiol-containing hormonal contraceptive medications can be 
continued while receiving investigational product, but their eff ectiveness may  be impacted. 
Therefore, barrier methods of contraception must be used for at least one full menstrual cy cle 
following completion of investigational product dosing.  
Medications m ay be used with caution and require oversight by [CONTACT_295429] -adm inistered 
with PF- 07321332/ritonavira
Drug Class Specific Medication Clinical Comments
Antidepressant Citalopram, escitalopram  No data available 
Sertraline, Bupropi[INVESTIGATOR_295389]-administration may decrease sertraline 
and bupropi[INVESTIGATOR_295390]-administration with ritonavir increases 
the level/effect of trazodone by [CONTACT_295430]/intestinal enzyme CYP3A4 
metabolism. Further, trazodone may 
decrease the level/effect of ritonavir by P -
glycoprotein (MDR1) efflux transporter.  
To be used w ith caution. 
Anticancer Agents: Dasatinib, imatinib, nilotinib, 
venetoclax,  
Vincristine, Vinblastine Co-administration of ritonavir may increase 
the concentration of dasatinib and nilotinib.   
Coadm inistration of ritonavir with 
venetoclax may increase concentration of 
venetoclax and increase the risk of tumor 
lysis syndrome. 
Con-administration with ritonavir may 
increase the concentrations of vincristine 
and vinblastine and develop significant 
hematologic or gastrointestinal side effects. 
  
Antihypertensive 
Angiotensin receptor 
blockers: Losartan, valsartan Co-administration with ritonavir increases 
the level/effect of losartan by [CONTACT_295430]/intestinal enzyme CYP3A4 
metabolism. Ritonavir increases the 
level/effect of valsartan by [CONTACT_295431]. To be used with caution. 
Antiparasitic: Atovaquone 
Quinine Co-administration with ritonavir may 
decrease the concentration of atovaquone 
Co-administration with ritonavir may 
decrease concentration of quinine 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 107Medications m ay be used with caution and require oversight by [CONTACT_295429] -adm inistered 
with PF- 07321332/ritonavira
Drug Class Specific Medication Clinical Comments
Antipsychotic: Haloperidol Co-administration with ritonavir increases 
the level/effect of haloperidol by [CONTACT_295430]/intestinal CYP3A4 metabolism. 
Haloperidol and ritonavir bo th increase 
QTc interval. To be used w ith caution. 
Bronchodilator: Theophylline Co-administration  with ritonavir may 
decrease theophylline concentration. 
Corticosteroids Fluticasone RTV tw ice daily increases fluticasone AUC 
350-fold 
HIV Antivirals 
Non-nucleoside 
reverse transcriptase 
inhibitors 
CCR5 -antagonist 
Integrase inhibitors Delavirdine 
Maraviroc 
Raltegravir Co-administration may increase ritonavir 
concentration 
Co-administration may increase maraviroc 
concentration 
Raltegravir concentrations may be 
decreased 
Hypoglycemics Canagliflozin Co-administration may decrease 
canagliflozin concentration 
Narcotic and 
Treatment for Opi[INVESTIGATOR_295391]-administration may increase 
concentration of tramadol 
PDE -5 Inhibitors for 
treatment of erectile 
dysfunction Sildenafil –ED (m ax dose 25 mg 
every 48 hours) 
Avanafil 
Tadalafil (max dose 10 mg every 
72hours) 
Vardenafil (max dose 2.5 mg every 
72hours) Risk of visual disturbances, hypotension, 
prolonged erection, and syncope 
Steroids (systemic) Dexamethasone 
Prednisone Co-administration with ritonavir may 
increase dose of dexamethasone and 
prednisone and may increase the risk for 
development of systemic corticosteroid 
effects including Cushing’s syndrome and 
adrenal suppression 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 108Medications m ay be used with caution and require oversight by [CONTACT_295429] -adm inistered 
with PF- 07321332/ritonavira
Drug Class Specific Medication Clinical Comments
Stimulant Methamphetamine Co-administration with ritonavir may 
increase concentration of 
methamphetamine 
a Note: If a drug is not listed, it should not automatically be assumed it is safe to co -administer   

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page [ZIP_CODE].9. Appendix 9: Signs and Symptoms Attributable to COVID -19
Table 2. Signs and Symptoms Attributable to COVID- 19
Daily Sign and Symptom Collection31Entry 
Criterion#3 
Targeted 
(used for 
study entry)Daily Signs and 
Symptom  
CollectionTargeted 
Symptoms For 
Analysis
Cough X X X
Shortness of breath or difficulty breathing X X X
Fever (documented temperature >38 ˚C [100.4˚F]) or 
subjective fever (eg, feeling feverish)X
Feeling feverish X X
Chills or shivering X X X
Fatigue (low energy or tiredness) X X
Muscle or body aches X X X
Diarrhea (loose or w atery stools) X X X
Nausea (feeling like you wanted to throw  up) X X X
Vom iting (throw  up) X X X
Headache X X X
Sore throat X X X
Stuffy or runny nose X X X
Loss of smell X
Loss of taste X

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page [ZIP_CODE].10. Appendix 10: Country -Specific Requirements
10.10.1. [LOCATION_009] 
Contrat Unique
1.GCP Training 
Before enrolling an y participants, the investigator and an y subinvestigators will 
complete the [COMPANY_007] -provided Good Clinical Practice training course (“[COMPANY_007] GCP 
Training”) or training deemed equivalent b y [COMPANY_007]. An y investigators who later join 
the study  will do the same before performing study -related duties. For studies of 
applicable duration, the investigator and subinvestigators will complete [COMPANY_007] GCP 
Training or equivalent every  [ADDRESS_360075], and of any  serious breaches of this protocol or of ICH GCP that 
the investi gator becomes aware of.
4.Termination Rights 
[COMPANY_007] retains the right to discontinue development of PF- 07321332 at an y time.
10.10.2. Japan
A Protocol Administrative Change Letter was issued on 22 July 2021 to provide Japan 
country  specific guidance regarding Exclusion Criterion #6 .  
Exclusion Criterion #6: Known HIV infection with a viral load >400 copi[INVESTIGATOR_014]/mL  or taking 
prohibited medications for HIV treatment (from known medical history  within past 6 months 
of the screening visit).
If HIV infection is known by  [CONTACT_295432] (if any ), the 
investigators must consult with the patient’s HIV treatment specialist to confi rm that the HIV 
RNA level has been monitored at an appropriate frequency  and the HIV RNA level has been 
≤400 copi[INVESTIGATOR_014]/mL  during the past 6 months before the screening visit in order to assess the 
study  eligibility  of that patient.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 111Rationale: There is a risk for patients with uncontrolled HIV to develop resistance to 
ritonavir which is being administered with PF -07321332. According to the HIV treatment 
guideline in Japan, even if there is an occasional increase in the amount of HIV RNA in the 
blood to about 20 -500 copi[INVESTIGATOR_014]/mL , the same treatment may  be continued. The guideline 
recommends a resistance test when HIV RNA levels exceed 500 copi[INVESTIGATOR_014]/mL.
.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page [ZIP_CODE].11. Appendix 11: Protocol Amendment History
Amendment 1 (02 July 2021)
Overall Rationale for the Amendment: The protocol was amended to incorporate 
regulatory  feedback.
Section # and Name [CONTACT_23688]
1.1 Synopsis
Section 3.0 Objectives, 
Endpoints and Estimands
Section 9.3.4 Secondary 
Endpoint(s)/Estimand(s) 
AnalysesRemoval of COVID -19 severity 
ranking endpoint.To address regulatory feedback.
1.1 Synopsis
Section 3.0 Objectives, 
Endpoints and Estimands
Section 9.3.4 Secondary 
EndpointsSecondary endpoint related to 
medical visits will include 
hospi[INVESTIGATOR_602].To align with program strategy.
1.2 Schema Schema footnote w as updated. For clarification.
1.3 Schedule of Activities 
Section [IP_ADDRESS] Global 
Impression Questions
Section 9.3.[ADDRESS_360076] 
updated to 5 days in inclusion 
criteria. New  wording: Confirmed 
SARS -CoV- 2 infection as 
determ ined by [CONTACT_937] -PCR in any 
specimen collected w ithin 5 days 
prior to randomization.To improve operational feasibility.
Section 5.2 Exclusion 
CriteriaExclusion criterion updated with 
new wording:  Prior to current 
disease epi[INVESTIGATOR_1865], any confirmed 
SARS -CoV- [ADDRESS_360077] 
(antigen or nucleic acid) from any 
specimen collection.For clarification.
Section 9 Clarifications made to text in 
statistical section.To address regulatory feedback.
Section 9.2 Analysis Sets Updated mITT1 definition. To address regulatory feedback.
Typographical errors w ere 
corrected and minor edits w ere 
made.For clarification and to ensure 
consistency.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 113Amendment 2 ([ADDRESS_360078] 2021)
Overall Rationale for the Amendment: The primary  anal ysis set (mITT) h as been refined 
to include just those participants who were treated ≤3 day s after COVID -19 sy mptom onset 
(mITT). There is precedent for earl y treatment of acute respi[INVESTIGATOR_295392]. This change allows for optimization of the primary  anal ysis 
set by  [CONTACT_295433] <5 days to ≤3 day s.
Section # and Nam e Description of Change Brief Rationale
Synopsis Describes changes made in 
Sections 3, 4 and 9 below .To summarize changes made in the 
document.
Section 1
Schedule of ActivitiesMinor edits to footnotes. To clarify use of brackets and 
procedure requirements associated w ith 
thelocation for expected visits.
Section 3
Objectives, Endpoints and 
EstimandsPrimary estimand changed to 
specify inclusion of 
participants who did not 
receive COVID -19 
therapeutic mAbs and who 
were treated ≤3 days after 
COVID -19 symptom onset.
A key secondary efficacy 
endpoint (proportion of 
participants with 
COVID -19-related 
hospi[INVESTIGATOR_295393] 
28) w as added.Due to uncertainty on the effect of 
time from symptom onset relative 
to initiation of treatment on the 
effectiveness of an antiviral, a 
change has been made to the 
primary analysis set. Primary 
analysis is no w based upon the 
mITT, which includes those 
participants treated ≤3 days after 
COVID -19 symptom onset.
The key secondary efficacy 
endpoint was added  as a 
consequence of the change in 
primary efficacy analysis and the 
analysis will include participants 
regardless of their symptom onset.
Section [ADDRESS_360079] those 
participants who were treated ≤3 days 
after COVID -19 symptom onset 
(mITT). Sample size has been adjusted, 
and the analysis of all participants is 
now a secondary analysis. 
Section 6
Study Intervention(s) and 
Concomitant TherapyGuidance added regarding 
shippi[INVESTIGATOR_295394].Stability data demonstrate that if the 
total duration of transit is less than 
24hours, temperature monitoring is not 
required.
Section 6
Blindin g of the SponsorLanguage was added to clarify 
that the study will be unblinded To provide additional information and 
clarification in the process of 
unblinding.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 114Section # and Nam e Description of Change Brief Rationale
after all participants have 
completed the Day [ADDRESS_360080] is not at end 
of study, but rather is at Day 34 visit.
Section 9 Statistical 
Consid erationsPrimary estimand changed to 
specify patients who did not 
receive COVID -19 
therapeutic mAb, andwho 
were treated ≤3days after 
COVID -19 symptom onset.
mITT analysis set added that 
includes participants who did 
not receive nor were 
expected to recei ve 
COVID -19 therapeutic mAb, 
and who were treated 
≤3days after COVID -19 
symptom onset.  
Changed the analysis set for 
the primary efficacy analysis 
from mITT1 to mITT. Key 
secondary efficacy endpoint 
was added and analysis will 
be conducted using the 
mITT1 analysis set.  
Enrollment of participants 
that had COVID -19 
symptom onset >3 days prior 
to randomization is expected 
to be approximately 25% and 
will be limited to 
approximately 
1000 participants.
Updated total sample size 
(from 2260 to approximately 
3000 participants).Due to uncertainty on the effect of time 
from symptom onset relative to 
initiation of treatment on the 
effectiveness of an antiviral, a change 
has been made to the primary analysis 
set. Primary analysis is now based upon 
the mITT, which includes those 
participants treated ≤3 days after 
COVID -19 symptom onset. Additional 
section changes are a consequence of 
the change in primary efficacy analysis. 
Primary efficacy analysis set is now 
based on participants treated ≤[ADDRESS_360081] at 
screening updated from under 
60years to under 50 years to be 
consistent with the SoAFor clarification and to ensure 
consistency.
Appendix 10 Added Japan country -specific 
guidance regarding Exclusion 
Criterion #6. To incorporate country -specific 
changes into the global protocol.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 115Section # and Nam e Description of Change Brief Rationale
Throughout the protocol Typographical errors w ere 
corrected and minor edits w ere 
made.For clarification and to ensure 
consistency.
Amendment 3 (26 October 2021)
Overall Rationale for the Amendment: To include an additional planned interim analy sis 
for efficacy  and futility  to be done after approximately  70% of participants in the mI TT 
analysis set complete the Day  28 assessments (ie, 28 day s after randomization).
Section # and Nam e Description of Change Brief Rationale
Section 1.1
SynopsisDescribes changes made in 
Sections 4 and 9 below .
Correction made in 
description of the first interim 
analysis to show that it was 
planned for efficacy and 
futility, rather than efficacy 
and safety.
Primary 
Endpoint(s)/Estimand(s) 
Analysis: updated to include 
primary analysis conducted 
for 2 planned interim analyses .
Added approximately to the 
following statement: 
Enrollment of participants that 
had COVID -19 symptom 
onset >3 days prior to 
randomization is expected to 
be approximately 25%, and 
will be limited to a total of 
approximately 
1000 participants
Sample Size Determination: 
text updated: To allow  for a 
5% dropout rate, enrollment 
will be stopped after 
approximately [ADDRESS_360082] 
1779 participants are available 
for the primary analysis.
Sample size increased from 
approximately 3000 
participants to approximately To summarize changes made in the 
document.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 116Section # and Nam e Description of Change Brief Rationale
3100 participants due to 
addition of second interim 
analysis.
Section 1.2
SchemaAdded new Schema per PACL 
[ADDRESS_360083] a formatting error.
Section 1.3
Schedule of ActivitiesInformation added from 
12August 2021 PACL under 
“other laboratory 
assessments”
Clarifications made to Day 1 
and Day 5 PK sample 
collection text. 
ET pregnancy added. 
Text added to clarify that 
targeted physical 
examinations will be 
completed at the following in -
person visits: Days 14 and 34, 
and ET (prior to Day 34). 
Text from Sect ion 7.1.[ADDRESS_360084] screening 
eGFR result of 
<45mL/min/1.73m2should 
result in discontinuation of 
study intervention.
Staff revie w of study diary 
added at Days [ADDRESS_360085] few days of study.
Text added to footnotes to 
clarify that t elemedicine visits 
may be conducted in -person at
the discretion of the 
investigator.To update as per PACL [ADDRESS_360086] 2021 
and to clarify other language in the 
Schedule of Assessments.
Section 2.3.3 
Over all Benefit/Risk 
ConclusionText updated to clarify that the 
E-DMC will be responsible for 
monitoring the safety of 
participants at regularly scheduled 
intervals throughout the duration 
of the study and for assessing 
efficacy and futility at the time of 
the interim analyses.To be consistent with the rest of the 
document.
Section 4.1
Overall DesignSample size updated from 
approximately 3000 
participants to approximately
3100 participants due to To provide a more comprehensive 
description of the overall study design.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 117Section # and Nam e Description of Change Brief Rationale
addition of second interim 
analysis.
Language added to Section 4.1 
information already included 
in the protocol, in order to 
describe the expected 
percentage of participants who 
will fall in to the mAb 
treatment group and the 
cappi[INVESTIGATOR_295395] >3 days.
Added information about the 
addition of a second interim 
analysis. 
Section 6.3.2
Blinding of the SponsorLanguage was added to provide 
additional information about the 
study unblind ing plan.To provide additional information so 
that an unblinded submission team 
could be formed at the time of an 
interim analysis f or preparing unblinded 
analyses and documents to support 
regulatory activities .
Section 7.1
Discontinuation of Study 
InterventionUpdated text about 
discontinuation of study 
intervention due to an AE.
Removed requirement to 
discontinue study intervention 
if a participant is hospi[INVESTIGATOR_295396].
Added that i n the event a 
participant is hospi[INVESTIGATOR_9651], 
study intervention may 
continue to be administered, 
as feasible, and based on 
medical judgement of the 
investigator.AE language updated to clarify that 
not all AEs will result in 
discontinuation of study 
intervention.
Updated in order to allow  the 
investigator to use medical 
judgment to decide w hether 
participant will remain on study 
intervention during hospi[INVESTIGATOR_059].
Section 9 
Statistical Considerations9.3.1 General 
Considerations: Mean and 
SEM removed from tabular 
summaries of the 
Kaplan -Meier curves.
9.3.2 Primary 
Endpoint(s)/Estimand(s) 
Analysis: updated to include 
primary analysis conducted 
for 2 planned interim 
analyses .With the addition of a second interim 
analysis while controlling for the 
overall significance level of 5%, an 
adjustment is applied to the sample size 
such that approximately 60 additional 
participants are needed for the primary 
analysis resulting in a total of 1779 
participants instead of the original 1717 
participants. Therefore, the updated 
total sample size based on this second 
interim analysis is 3100 participants 
instead of 3000 participants.

PF-07321332
Protocol C4671005Final Protocol Amendment 4, 20 November 2021
PFIZER CONFIDENTIAL 
Page 118Section # and Name [CONTACT_23688]
 
 
 
 
•9.4. Interim Analyses: 
Second interim analysis added. 
•9.5 Sample Size 
Determination: text updated: To allow for a 5% dropout rate, enrollment will be stopped after approximately [ADDRESS_360087] 
1779 participants are available for the primary analysis.
•Total sample size changed 
from 3000 to 3100 participants.
Section 10 
Supporting documentation 
and Operational considerations•Second interim analysis 
added.To add the addition of the second 
interim analysis to the Data Monitoring Committee description under Committee Structure.
Appendix [ADDRESS_360088] of 
precautionary and prohibited 
medications
Throughout the protocol Typographical errors were 
corrected and minor edits were made.For clarification and to ensure 
consistency.C
CI
PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page [ZIP_CODE].12. Appendix 12: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
3CL 3C-like protein
6MP mercaptopurine
Abs absolute
AE adverse event
AESI adverse events of special interest
ALT alanine aminotransferase
aPTT activated partial thromboplastin time
ARDS acute respi[INVESTIGATOR_273471] -time curve
AV atrioventricular
-hCG beta-human chorionic gonadotropin
BID twice a day
bpm beats per minute
BMI body  mass index
BUN blood urea nitrogen
CABG coronary  artery  by[CONTACT_295434]5 chemokine receptor t ype 5
CD4 cluster of differentiation 4
CDC [LOCATION_002] Centers for Disease Control and Prevention
CFR Code of Federal Regulations
CI Confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD chronic kidney  disease
CKD -EPI [INVESTIGATOR_295397] 2 carbon dioxide (bicarbonate)
CONSORT Consolidated Standards of Reporting Trials
COVID -[ADDRESS_360089] acting antivirals
DAIDS Division of AIDS
DDI drug-drug interaction 
DILI drug-induced liver injury
DNA deox yribonucleic acid
dNHBE differentiated normal human bronchial epi[INVESTIGATOR_295398] 90 concentration required for 50% effect
ECC emergency  contact [CONTACT_295435] d ysfunction
EDB exposure during breastfeeding
E-DMC external data monitoring committee
EDP exposure during pregnancy
eGFR epi[INVESTIGATOR_295399]-5D EuroQol -[ADDRESS_360090]-in-human
FSH follicle -stimulating hormone
FU follow up
fu fraction of unbound drug in serum or plasma
GCP Good Clinical Practice
GFR glomerular filtration rate
GGT gamma -glutamy l transferase
GH good health
GLP Good Laboratory  Practice
HCP health care professional; health care provider
HCV hepatitis C virus
HDPE high-densit y pol yethylene

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 121Abbreviation Term
HF heart failure
HIV human immunodeficiency  virus
HMG -CoA 3-hydroxy -3-methy lglutary l co-enzyme
HR heart rate
HRT hormone replacement therap y
hsCRP high-sensitivity  C-reactive protein
HTA health technologies assessment
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation
ICU intensive care unit
ID identification
Ig immunoglobulin
IMP investigational medicinal product
IND investigational new drug
INR international normalized ratio
IP investigational product
IP manual investigational product manual
IPAL Investigational Product Accountability  Log
IRB institutional review board
IRT interactive response technology
IV intravenous(l y)
IWR interactive Web -based response
KM Kaplan Meier
LDH lactate deh ydrogenase
LFT liver function test
mAb monoclonal antibody
MAD multiple ascending dose
MDR1 multidrug resistance mutation
mITT modified intent -to-treat 
MMRM mixed -effect model repeated measure
msec millisecond
MRC -5 human lung epi[INVESTIGATOR_1663] -5
N/A not applicable
NHP non-human primate
NIAI D National Institute of Allergy  and Infectious Diseases
NIH National Institutes of Health
NIMP noninvestigational medicinal product
NP nasophary ngeal
PCI percutaneous coronary  intervention
PDE -5 phosphodiesterase

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 122Abbreviation Term
PK pharmacokinetic(s)
PP per-protocol
PRO patient reported outcomes
PT prothrombin time
PVC premature ventricular contraction/complex
q12h every  12 hours
QTc corrected QT
QTcF corrected QT (Fridericia method)
QTL quality  tolerance limit
RBC red blood cell
RT-PCR reverse transcription polymerase chain reaction
RTV ritonavir
SAD single ascending dose
SAE serious adverse event
SAP statistical analy sis plan
SARS -CoV -[ADDRESS_360091] upper limit of normal
US [LOCATION_002]
USPI [INVESTIGATOR_185578] I nformation; [LOCATION_002] Package 
Insert
VAS visual analogue scale
WBC white blood cell
WHO World Health Organization
WOCBP woman/women of childbearing potential
WPAI Work Productivity  and Impairment

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page [ZIP_CODE].REFERENCES
1. Kalbfleisch JD, Prentice RL . In The statistical analysis of failure time data .  Edited 
by.:  John Wiley  & Sons, I nc; 1980.
2. New data show treatment with L illy's neutralizing antibodies bamlanivimab (LY -
CoV555) and etesevimab (LY -CoV016) together reduced risk of COVID- 19 
hospi[INVESTIGATOR_295400]  70 percent . 2021. Available from: 
http://lilly .mediaroom.com/2021 -01-26- New -data-show -treatment -with-Lilly s -
neutralizing -antibodies- bamlanivimab -LY-CoV555 -and-etesevimab -LY-CoV016-
together -reduced -risk-of- COVID - 19- hospi[INVESTIGATOR_602] -and-death -by-70-percent. 
Accessed o n: [ADDRESS_360092] Sheet for Health Care Providers. Emergency  
Use Authorization (EUA) of Bamlanivimab and Etesevimab. Report Number: 04 
June 2021. 2021. Available from: https://www.fda.gov/media/145802/download. 
Acces sed on: 01 July  2021.
4.
World Health Organization. 2019- nCoV outbreak is an emergency  of international 
concern. 31 Jan 2020. Available from: https://www.euro.who.int/en/health -
topi[INVESTIGATOR_1102]/health- emergencies/coronavirus -covid-19/news/news/2020/01/2019- ncov -
outbreak-is-an-emergency -of-international -concern. Accessed on: 22 March 2020.
5. World Health Organization. WHO Situation Report 51 Coronavirus disease 2019 
(COVID -19). 11 March 2020. Available from: https://www.who.int/docs/default -
source/coronaviruse/situation -reports/20200311 -sitrep-51- covid-
19.pdf?sfvrsn=1ba62e57_10. Accessed on: [ADDRESS_360093] by  [CONTACT_214363] S ystems Science 
and Engineering (CSSE) at Johns Hopkins University  (JHU). Available from: 
https://coronavirus.jhu.edu/map.html. Accessed on: Jun 2020.
7. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the 
Coronavirus Disease 2019 (COVID -19) Outbreak in China: Summary  of a Repo rt of 
[ZIP_CODE] Cases From the Chinese Center for Disease Control and Prevention. JAMA. 
2020;323(13):1239 -42.
8. Dochert y AB, Harrison EM, Green CA, et al. Features of 20 133 [LOCATION_006] patients in 
hospi[INVESTIGATOR_61010]- 19 using the ISARIC WHO Clinical Characterisation Protocol: 
prospective observational cohort study . BMJ. 2020;369:m1985.
9. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, 
Comorbidities, and Outcomes Among 5700 Patients Hospi[INVESTIGATOR_45086] -19 in 
the [LOCATION_001] City  Area. JAMA. 2020;323(20):2052 -59.
10. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with 
coronavirus disease 2019: retrospective stud y. BMJ. 2020;368:m1091.
11. Cummings MJ, Baldwin MR, Abrams D, et al. Epi[INVESTIGATOR_623], clinical course, a nd 
outcomes of criticall y ill adults with COVID- 19 in [LOCATION_001] Cit y: a prospective 
cohort study . Lancet. 2020;395([ZIP_CODE]):1763 -70.
12. Mehta P, McAuley  DF, Brown M, et al. COVID -19: consider cy tokine storm 
syndromes and immunosuppression. Lancet. 2020;395([ZIP_CODE]):1033-34.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page [ZIP_CODE]. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospi[INVESTIGATOR_45077] 
2019 Novel Coronavirus -Infected Pneumonia in Wuhan, China. JAMA. 
2020;323(11):1061 -69.
14. Dochert y AB, Harrison EM, Green CA, et al. Features of 20,13 3 [LOCATION_006] patients in 
hospi[INVESTIGATOR_61010]-19 using the ISARIC WHO Clinical Characterisation Protocol: 
prospective observational cohort study . BMJ. 2020;369:m1985.
15. Cao B, Wang Y, Wen D, et al. A Trial of Lopi[INVESTIGATOR_054] -Ritonavir in Adults Hospi[INVESTIGATOR_95264] -19. N Engl J Med. 2020;382(19):1787 -99.
16. Cavalcanti AB, Zampi[INVESTIGATOR_295401], Rosa RG, et al. Hy droxy chloroquine with or without 
Azithromy cin in Mild -to-Moderate Covid -19. N Engl J Med. 2020;383(21):2041 -52.
17. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of Hy droxychloroquine Usage 
in [LOCATION_002] Veterans Hospi[INVESTIGATOR_21391]- 19. Med (N Y). 2020;1(1):114-
[ADDRESS_360094] treatment for COVID-19. 
May 2020. Available from: https://www.fda.gov/news -events/press-
announcements/fda- approves- first-treatment -covid -
19?utm_medium=email&utm_source=govdelivery. Accessed on: 29 Jun 2021.
19. Beigel JH, Tomashek KM, Dodd L E, et al. Remdesivir for the Treatment of Covid -
19 
- Final Report. N Engl J Med. 2020;383(1 9):[ADDRESS_360095] Care on 
Clinical Status at 11 Days in Patients With Moderate COVID -19: A Randomized 
Clinical Trial. JAMA. 2020;324(11):[ADDRESS_360096], Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid -19 
-Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):[ADDRESS_360097] 
neglected and emerging RNA viruses. Antiviral R es. 2018;153:85-94.
23. Santos J, Brierley  S, Gandhi MJ, et al. Repurposing Therapeutics for Potential 
Treatment of SARS -CoV -2: A Review. Viruses. 2020;12(7).
24. Joshi S, Parkar J, Ansari A, et al. Role of favipi[INVESTIGATOR_295402]-19. 
Int J I nfect Dis. 2021;102:[ADDRESS_360098] sheet for health care providers emergency  
use authorization (EUA) of Sotrovima. Report Number: 04 June 2021. Available 
from: https://www.fda.gov/media/149534/download. Accessed on: 01 Ju ly 2021.
26. US Food and Drug Administration. US Food and Drug Administration (2021). Fact 
sheet for health care providers emergency  use authorization (EUA) of Regen- Covtim 
(casirivimab and imdevimab). Report Number: 04 June 2021. Available from: 
https://w ww.fda.gov/media/145611/download. Accessed on: 01 July  2021.
27. Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) 
structure: basis for design of anti -SARS drugs. Science. 2003;300(5626):1763 -7.
28. [COMPANY_007]. I nvestigator's Brochure PF-07321332. June 2021. Version 3.0. Data on file.
29. National Institutes of Health. The COVID -19 treatment guidelines panel’s statement 
on the emergency  use authorizations of anti -SARS -CoV -2 monoclonal antibodies for 
the treatment of COVID -19. Report Nu mber: 16 June 2021. Available from: 

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page 125https://www.covid19treatmentguidelines.nih.gov/therapi[INVESTIGATOR_014]/statement -on-anti-sars-
cov-
2-monoclonal -antibodies -eua/. Accessed on: 01 July  2021.
30. Levey  AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerul ar 
filtration rate. Ann Intern Med. 2009;150(9):604- 12.
31. US Food and Drug Administration. Assessing COVID -19-Related Sy mptoms in 
Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological 
Products for COVID -19 Prevention or Trea tment. 2020. Available from: 
https://www.fda.gov/regulatory -information/search -fda-guidance -
documents/assessing -covid -
19-related -symptoms -outpatient -adult -and-adolescent -
subjects -clinical -trials
-drugs. Accessed on: 25 Mar 2021.
32. US Bureau of Labor Statistics.  Effects of COVID- 19 Pandemic on Productivity  and 
Costs Statistics. Available from: https://www.bls.gov/covid19/effects-of- covid - 19-
pandemic -
on-productivity -and-costs -statistics.htm. Accessed on: 08 Jun 2021.
33. Reilly  MC, Zbrozek AS, Dukes EM. The validit y and reproducibility  of a work 
productivity  and activity  impairment instrument. Pharmacoeconomics. 
1993;4(5):353 -
65.
34. Rabin R, Gudex C, Selai C, et al. From translation to version management: a history  
and review of methods for the cultu ral adaptation of the EuroQol five -dimensional 
questionnaire. Value Health. 2014;17(1):70 -6.
35. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ -5D- 5L: mappi[INVESTIGATOR_74046] -5D- 5L to EQ -5D- 3L value sets. Value Health. 2012;15(5):708 -15.
36. Ram os-Goni JM, Pi[INVESTIGATOR_1946] -Prades J L, Oppe M, et al. Valuation and Modeling of EQ -5D-
5L Health States Using a Hy brid Approach. Med Care. 2017;55(7):e51- e58.
37. Yang Y, Brazier J, L ongworth L . EQ-5D in skin conditions: an assessment of validity  
and responsiveness. Eur J Health Econ. 2015;16(9):[ADDRESS_360099] AS, Golicki D, et al. Measurement properties of the EQ-5D- 5L 
compared to the EQ -5D- 3L across eight patient groups: a multi -country  study . Qual 
Life Res. 2013;22(7):1717-27.
39. Herdman M, Gudex C, Lloy d A, et al. Development and preliminary  testing of the 
new five -level version of EQ -5D (EQ -5D- 5L). Qual L ife Res. 2011;20(10):1727 -36.
40. Agborsangay a CB, Lahtinen M, Cooke T, et al. Comparing the EQ -5D 3L and 5L : 
measurement properties and associa tion with chronic conditions and multimorbidity  
in the general population. Health Qual Life Outcomes. 2014;12:74.
41. EuroQol G. EuroQol --a new facility  for the measurement of health- related quality  of 
life. Health Policy . 1990;16(3):199-208.
42. U.S. Depa rtment of Health and Human Services NIoH, National Institute of Allergy  
and Infectious Diseases, Division of AIDS,. Division of AIDS (DAIDS) Table for 
Grading the Severity  of Adult and Pediatric Adverse Events, Corrected Version 2.1. 
July 2017. Available f rom: 
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf. Accessed 
on: 10 Jun 2021.
43. Benjamini Y, Hochberg Y. Controlling the false discovery  rate: a practical and 
powerful approach to multiple testing. Journal of the Royal statistical society : series 
B. 1995;57(1):289 -300.

PF-07321332
Protocol C4671005
Final Protocol Amendment 4, 20November 2021
PFIZER CONFIDENTIAL 
Page [ZIP_CODE]. Cui L , Hung HM, Wang SJ. Modification of sample size in group sequential clinical 
trials. Biometrics. 1999;55(3):853-7.
45. US Food and Drug Administration. Guidance for industry : adaptive design clinical 
trials for drugs and biologics November 2019. . Report Number: 16 June 2021. 
Available from: https://www.fda.gov/regulatory -information/search- fda-guidance -
documents/assessing -covid -19-related -symptoms -outpatient -adult -and-adolescent -
subjects -clinical -trials
-drugs. Accessed on: 01 July  2021.

'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH	

 
  

	
'RFXPHQW 7LWOH	

 
  

	
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\

""
	 	##$ % &&


""
	 	#
#		 % &&
[COMPANY_003]
[COMPANY_003]